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 Abstract 
The field of drug delivery has provided a solution to the limited efficacy and high toxicity 
of many drugs.  Nano-sized drug carriers are popular because their size allows for selective 
accumulation in the diseased area. Polysaccharides are non-toxic and biodegradable natural 
polymers that can serve as the basis for these nano-sized carriers. Polysialic acid (PSA) is such a 
polysaccharide with strong hydrophilicity that may reduce uptake by the reticuloendothelial 
system and prolong drug circulation. In this study, we developed PSA-based nanocarriers, 
specifically micelles and nanoparticles, for improved drug delivery with improved efficacy and 
minimized toxicity. PSA-based micelle systems were developed via conjugation with two 
hydrophobic groups, decylamine (DA) and polycaprolactone (PCL). Nanoparticles were 
fabricated via ionic complexation of the negatively charged PSA with positively charged N, N, 
N-trimethyl chitosan (TMC). All three nanocarriers possessed sizes close to 100 nm with low 
polydispersity (PDI) and high zeta potential values. Literature suggested that these characteristics 
would allow the nanocarriers to be physiologically stable and would facilitate passive 
accumulation within diseased areas. Rheumatoid arthritis (RA) was selected as the primary 
disease model for evaluation of our nanocarriers. PSA-PCL micelles and PSA-TMC 
nanoparticles showed low cytotoxicity, as demonstrated by high IC50 values (PSA-PCL: 10.5 ± 
1.7 mg/ml; PSA-TMC: 7.65 ± 0.07 mg/ml) to synovial cells, the so-called conductors of joint 
destruction in rheumatoid arthritis. The synovial cells were also used to demonstrate effective 
uptake of fluorescently tagged nanocarriers.  Three disease modifying anti-rheumatic drugs 
(DMARDs) were selected for loading into the nanocarriers.  Cyclosporine A (CyA) was 
encapsulated within the PSA-PCL micelles, while methotrexate (MTX), and dexamethasone 
(DM) were entrapped within the PSA-TMC nanoparticles. PSA-PCL micelles were loaded with 
 0.09 ± 0.02 mg CyA per mg of PSA- PCL, while PSA-TMC nanoparticles were loaded with 0.10 
± 0.03 mg MTX and 0.10 ± 0.02 mg DM per mg of PSA-TMC. Controlled release of the 
DMARDs from the nanocarriers was demonstrated. An in vitro model of rheumatoid arthritis 
was used to demonstrate the anti-inflammatory nature of the MTX- and DM-loaded PSA-TMC 
nanoparticles. To the author’s knowledge, this is the first time that PSA-based nanocarriers were 
successfully developed and evaluated for improved drug delivery.  
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1 
Chapter 1 Introduction 
Due to rapid clearance and random distribution, employment of many drugs is limited by 
low efficacy and non-site specific toxicity. Drug delivery provides a method to overcome the 
latter deficiencies. Among drug delivery systems, nanocarriers have been widely investigated 
because of their specific targeting to diseased tissues and potential for long circulation in human 
body. In this dissertation, we aimed to develop nano-sized systems based on polysaccharides 
with low-toxicity that could be used for the treatment of many diseases. Emphasis was given to 
the application of these systems to the treatment of rheumatoid arthritis (RA), a systemic 
autoimmune disorder.	  The polysaccharide polysialic acid (PSA) was used to develop nano-sized 
carrier systems to improve the efficacy of conventional therapeutics.	  	  PSA is a non-toxic, 
biocompatible, biodegradable, and non-immunogenic polysaccharide that has been found on the 
surface of both mammalian and bacteria cells. In prior studies reported by Gregoriadis et al, PSA 
had been used to extend circulation time of drugs through conjugation [1-6]. By extending the 
circulation time, the chance of drug accumulation at the diseased tissues was increased.  
Although PSA had been used for conjugation, PSA had not been used in the formation of nano-
sized particulate carrier systems. We hypothesized that nanocarriers based on PSA would 
improve the therapeutic efficacy of conventional therapeutics used for RA and other diseases. 
Our goals were (1) to develop stable PSA-based nanocarriers; (2) characterize PSA-based 
nanocarriers in terms of size, morphology, stability, and drug loading; (3) evaluate in vitro 
potential of PSA-based nanocarriers in terms of cytotoxicity, cellular uptake, and efficacy.  
To achieve the goals, this dissertation developed two PSA-based micelle systems, PSA-
decylamine micelles (Chapter 3) and PSA-polycaprolactone micelles (Chapter 4), and one PSA-
  
2 
based nanoparticle system, PSA-N, N, N-Trimethyl chitosan nanoparticles (Chapter 5, 6). Details 
about the development, characterization, and evaluation of these PSA-based nanocarriers were 
described in separate chapters, including synthesis, size, stability, drug loading, cytotoxicity, 
cellular uptake, and anti-inflammatory efficacy. At last, all studies were summarized (Chapter 7) 
and future research direction was discussed (Chapter 8).  
 
 
 
 
 
 
 
 
 
  
3 
Chapter 2 Background and significance  
Drug delivery systems (DDSs) have been highly investigated to improve conventional 
treatments for diseases. Encapsulation by DDSs can endow drugs with tunable in vivo behavior 
without affecting the therapeutic efficacy. To date, DDS-based on nanocarriers have drawn much 
attention due to their (1) good outcome in terms of preferable accumulation in tissues with 
enhanced permeability and retention effect (EPR) and (2) ability to escape recognition and 
clearance by reticuloendothelial system (RES). Additionally, targeting moieties on these 
nanocarriers can further increase tissue specificity and improve efficacy. Polysaccharides, as 
biodegradable and biocompatible macromolecules with low immunogenicity, are ideal 
candidates for the development of nanocarriers. Several polysaccharides, including pullulan, 
dextran, chitosan, cellulose, and hyaluronic acid, have been used to prepare nanocarriers and 
improve treatment for diseases. Among many nanocarriers, polyethylene glycol (PEG) has been 
used to prolong circulation of drugs. However, usage of PEG may be limited for drug delivery by 
reported drawbacks, including high toxicity and frequent stimulation of immune responses. As 
an alternative, polysialic acid (PSA), as a polysaccharide, has functional similarity to PEG to 
prolong circulation and all the merits of polysaccharides. Therefore, PSA-based nanocarriers 
may serve as improved drug delivery systems. 
 
 
 
  
4 
2.1 Drug delivery  
 In the past 35 years, various drug delivery systems had been designed and 
commercialized based on medical needs [7]. The principle of drug delivery was to optimize in 
vivo behavior of drugs via passive targeting and active targeting. Passive targeting was a 
methodology to increase the ratio of drugs at desired/non-desired organs, tissues, and cells via 
physical and chemical interaction, such as hydrophobic and electrostatic interactions, size, and 
mass. As an example, tumor tissues possessed poorly organized vasculature, and 
macromolecules preferably extravasted at these sites due to enhanced permeability, an effect 
known as EPR. Therefore, many anti-tumor drug carriers were designed with EPR in mind.  
Active targeting was a methodology used in conjunction with passive targeting to increase drug 
delivery to targeted organs, tissues, and cells via biological interaction, such as antigen-antibody 
and ligand-receptor binding. Additionally, drug carriers could be developed with stimuli-
sensitive materials. Selective delivery of drugs could be achieved only with the presence of 
specific stimuli, such as pH, temperature, and chemicals.   
To date, the most investigated drug carriers include polymer-drug conjugates, liposomes, 
nanoparticles, micelles, and dendrimers. Polymer-drug conjugates were the earliest drug carriers 
and dated back to 1950s. Most polymer-drug conjugates could decrease drug toxicity, alter drug 
distribution, and increase therapeutic efficacy [8]. Liposomes were first developed in the early 
1970s. Composed of a lipid bilayer, liposomes are structurally similar to cell membrane. In the 
past, liposomes had been extensively investigated as carrier systems of drugs and vaccines for 
many diseases, such as cancers and infections. Despite a prolonged retention time and improved 
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targeting towards tumors, liposomes had some issues, including high pre-mature leakage of 
drugs and undesirable activation of the immune system [9].  
Micelles are self-assembled, nanosized colloidal particles with a hydrophobic core and 
hydrophilic shell [10]. The specialized structure makes micelles suitable carriers for poorly 
water-soluble drugs that account for approximately 25% of conventional, commercially available 
therapeutics and nearly 50% of candidates identified through screening techniques. Insoluble 
drugs often are characterized by poor bioavailability and rapid clearance after administration, 
characteristics that are associated with low therapeutic efficacy and high toxicity [11]. Micelles 
had been under investigation the past two decades to solve these issues [12]. Drug solubility has 
been greatly improved because of the hydrophilic shell of the micelle; and due to the tunable size 
of micelles, drugs could be directed to tissues where permeability was enhanced, particularly 
tumor and inflammatory tissue. Moreover, when modified by functional molecules that 
recognized molecular cues specific to diseased sites, micelles could achieve higher tissue 
specificity and cellular uptake [13, 14]. To date, numerous micelle drug delivery systems have 
been developed, with some achieving clinical testing. However, some concerns, including 
material toxicity, immunogenicity, low cellular uptake, short half-life, and tissue accumulation, 
have arisen [15].  
Nanoparticles are colloidal particles with high stability and drug loading capacity. 
Nanoparticles can be used to carry water-soluble and/or less water-soluble therapeutics by 
varying composites of nanoparticles [16]. Similar to micelles, nanoparticles are small enough to 
extravasate loose blood vessels and accumulate locally. This phenomena has been demonstrated 
in cancer and inflamed tissues and has been used to design and develop treatments for cancer and 
inflammatory diseases [17].  
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Detailed reviews of micelle and nanoparticle systems will be provided in the following 
sections. Drug delivery systems can be developed based on various materials, such as metals, 
synthetic polymers, and natural polymers. Polysaccharides are the selected materials for drug 
carriers in this study because our goals are to design and develop a platform for drug delivery 
with low toxicity and immunogenicity.  
2.2 Polysaccharides as the basis of Drug Delivery Systems 
2.2.1 Merits of polysaccharides 
Polysaccharides are a diverse class of polymeric materials of natural (animal, plant, algal) 
origin formed via glycosidic linkages of monosaccharides [18]. Dependent upon the nature of the 
monosaccharide unit, polysaccharides can have a linear or branched architecture. In addition to 
structural diversity, polysaccharides have a number of reactive groups, including hydroxyl, 
amino, and carboxylic acid groups, indicating the possibility for chemical modification [16]. 
Moreover, polysaccharide molecular weight can vary between hundreds and thousands of 
Daltons, further increasing diversity [19]. Herein, we will describe characteristics, including 
biocompatibility, solubility, potential for modification, and innate bioactivity, of several 
polysaccharides that lend credence to their potential for use in drug delivery systems. 
2.2.1.1 Biodegradability and Biocompatibility 
In contrast to many synthetic polymers, polysaccharides have very low (if any) toxicity levels 
[20-22]. For example, dextrans are biopolymers composed of glucose with α-1, 6 linkages, with 
possible branching from α-1, 2, α-1,3, and α-1,4 linkages, that exhibit low toxicity and high 
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biocompatibility. Consequently, dextrans have formed the basis of biocompatible hydrogels for 
controlled prolonged therapeutic release [23]. Likewise, dextrans have exhibited 
biocompatibility when they were formulated into microspheres, as suggested by a lack of an 
inflammatory response following subcutaneous injection into rats [24].  
Also owing to their native presence within the body, most polysaccharides are subject to 
enzymatic degradation. Through enzyme catalysis, polysaccharides can be broken down to their 
monomer or oligomer building blocks and recycled for use as storage, structural support, or even 
cell signaling applications [25]. For example, glycosidases are common, constituting 1%–3% of the 
human genome [26], and can readily catalyze the hydrolysis of many different glycosidic linkages 
[25]. In contrast to glycosidase, other enzymes are more polysaccharide specific. Hyaluronidase, 
for instance, specifically degrades the polysaccharide hyaluronic acid (HA) by cleaving β-1, 4 
linkages between D-glucuronic acid and D-N-acetylglucosamine, particularly in regions of high 
HA concentration [25]. Of note, some polysaccharides are particularly susceptible to degradation 
by lysosomal enzymes, including glycosidases, esterases, and proteases, following endocytosis 
[27]. For example, lysozyme, N-acetyl-β-D-glucosaminidase, and a range of proteases play a role 
in the degradation of chitosan [28, 29]. Thus, enzymatic degradation provides a mechanism of 
release for therapeutics associated with polysaccharide-based carrier systems [27].  
2.2.1.2 Solubility  
The functional groups along polysaccharide backbones, particularly hydroxyl and, to a 
lesser extent, amine groups, typically yield high aqueous solubility. However, this solubility can 
often be adjusted via monomer modification. For example, chitosan, composed of β-1, 4 linked 
N-acetyl-D-glucosamine and D-glucosamine, is prepared via deacetylation of chitin. By varying 
the degree of deacetylation of the parent compound, the solubility of chitosan in acidic 
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conditions can be tuned. Higher degrees of deacetylation correspond to an increased number of 
available, protonated free amino groups along the polysaccharide backbone and, consequently, 
enhanced solubility [30]. Likewise, O-acetylation of glucomannan, a polysaccharide formed via 
β-1, 4 linkage of D-mannose and D-glucose, can be used to modulate the formation of 
intermolecular hydrogen bonds with water, thereby altering aqueous solubility [31].  
2.2.1.3 Ease of Modification 
Polysaccharides are extremely amenable to modification. For example, glucose-based 
polysaccharides, such as amylose, amylopectin, glycogen, and cellulose, offer an abundance of 
free reactive hydroxyl groups [15]. Other polysaccharides possess both hydroxyl and carboxylic 
acid moieties that can be readily modified. For example, a review was recently published 
focusing on the derivatization of alginate, a polysaccharide composed of β-D-mannuronic acid 
and α-L-guluronic acid with 1,4 linkages. Alginate modification can be used to give rise to a 
variety of different physiological behaviors. For instance, hydroxyl group oxidation enhances 
biodegradability, while sulfonation generates a heparin-like polysaccharide with increased blood 
compatibility (see Section 2.4.1.5 for additional details on heparin) [32]. Modification of 
chitosan has also been extensively reviewed. Specifically, quaternization of the primary amines 
with various alkyl groups can be used to enhance solubility and alter bioactivity [33-35].  
2.4.1.4 Bioactivity 
Many polysaccharides possess innate bioactivity, particularly mucoadhesive, 
antimicrobial, and anti-inflammatory properties. Mucoadhesion refers to the interaction of a 
material with a mucosal layer, such as in the gastrointestinal (GI) tract, nasal pathway, or airway. 
Chitosan, the only natural, positively charged polysaccharide, is capable of binding to the 
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negatively charged mucosal layers through charge interactions [36-38]. Thus, numerous 
investigators have explored the use of chitosan for oral drug delivery. For neutral or negatively 
charged polysaccharides, such as HA, hydrogen bonding provides an alternative mechanism for 
mucoadhesion [39]. Several polysaccharides are also antimicrobial in nature. The cidal effects of 
chitosan, for example, are presumed to be due to a strong interaction of the protonated amines 
with the negatively charged bacterial cell wall [40]. Other polysaccharides are known to reduce 
inflammation. For instance, heparin, which is composed of repeating disaccharides of β-D-
glucopyranosiduronic acid or α-L-idopyranosiduronic acid linked to  
N-acetyl or N-sulfo-D-glucosamine, has the strongest negative charge of any polysaccharide, 
which enables interaction with a variety of proteins. Thus, anti-inflammatory activity is thought 
to be due to binding with immune-related acute phase and complement proteins [37, 41]. In 
addition, heparin can bind to the lysine-rich region of anti-thrombin, thereby catalyzing the 
inhibition of blood clotting [42, 43]. 
2.2.2 Polysialic acid 
Among polysaccharides, polysialic acid (PSA) is especially interesting. PSA is a linear 
homopolymer of α-2, 8-linked 5-N-glycolyneuraminic acid (Neu5Ac) with high water solubility 
and biocompatibility as well as low toxicity and immunogenicity. PSA is produced by 
pathogenic bacteria, as well as mammalian cells. Studies have shown that PSA was highly 
involved and had multifarious roles in a wide variety of biological, immunological, and 
pathological processes [44-47]. In pathogenic bacteria, a thick PSA coating was found on the cell 
surface, which allowed the bacterial easily evade host. Further studies found that the hydrophilic 
PSA coating was resistant to bindings of proteins and adhesion of immune cells, therefore, 
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endowed pathogenic bacteria with stealth properties in the physiological environment [48]. In 
mammals, production of PSA on cell surface can regulate the cell-cell and cell-extracellular 
matrix interaction and promote neutral plasticity by inhibiting cellular adhesion and migration 
[49, 50]. So far, no receptor for PSA has been reported in human body. The latter property has 
inspired Gregoridadis et al. proposed PSA as an anti-adhesive material with the potential to 
prolong drug circulation [1]. A series of studies were conducted. Improved stability and 
prolonged half-life were noticed in the polysialyated insulin [6], asparaginase [4, 5], and catalase 
[2, 3]. In addition, reduced immunogenicity and antigenicity of these exogenous proteins were 
observed with PSA conjugation. Therefore, PSA was concluded to form the “watery cloud” 
around proteins and to protect them from degradation and clearance [51, 52]. However, to the 
authors’ knowledge, PSA has not been used to prepare nanocarriers, such as micelles and 
nanoparticles, formulations that may provide improved drug delivery. Therefore, PSA has much 
potential that needs to be fully explored for nanocarrier-based drug delivery.  
2.2.3 Progress of Polysaccharide-Based Nanoparticle and micelle Systems for 
improved Drug Delivery 
Early clinical results suggest that micelles and nanoparticles should be designed and 
developed with careful attention towards material selection. Ideally, micelles and nanoparticles 
developed for drug delivery should be biodegradable and should have high stability, high 
biocompatibility, and low immunogenicity. Natural polysaccharides meet the latter requirements 
and can be used to develop micelles and nanoparticles in lieu of synthetic polymers. In addition, 
polysaccharides can be readily modified and exist in positive, negative, or neutral charge states. 
Finally, some polysaccharides are bioactive and can be used to augment the therapeutic efficacy 
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of an associated drug or can enhance the targeting ability of a carrier system [32, 53]. Despite 
these advantages, polysaccharide-based micelle and nanoparticle systems are still under 
development and the outcomes have not met the clinical need. Here in, we will: (1) provide a 
more detailed depiction of the advantages offered by polysaccharides; (2) discuss the progress 
that has been made towards the application of polysaccharide-based micelles and nanoparticles 
to drug delivery; and (3) offer suggestions for future research to expedite translation of 
polysaccharide-based drug delivery systems from the laboratory to a clinically relevant setting.  
2.2.3.1 Passive targeting delivery systems 
Several polysaccharides have been used to develop micelles and nanoparticles for drug 
delivery. The structures of commonly used polysaccharides are given in Figure 1. The numerous 
functionalities along backbone of polysaccharides facilitate attachment of hydrophobic moieties 
and reaction with other composition that can be used to initiate self-assembly to micelles and 
form nanoparticles, respectively. The most prevalent hydrophobic groups used in micelle 
formation are provided in Table 1.  
2.2.3.1.1 Pullulan-Based Systems 
Pullulan is a water-soluble, neutral, non-toxic bacterial exopolysaccharides [54]. Since 
Akiyoshi et al. first reported cholesterol-bearing pullulan (CHP) as a self-aggregated colloidal 
system with high stability [55, 56], numerous studies related to or based on CHP have been 
carried out. In the original report, CHP was synthesized by grafting 1.6 cholesterol groups to 
every 100 glucose units on pullulan (Mw 55,000 g/mol, Mw/Mn = 1.54) in a random manner. The 
average hydrodynamic radius of CHP self-aggregates was measured by dynamic light scattering 
(DLS) and determined to be 13.3 nm. Morphology studies by negatively stained transmission 
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electron microscopy (TEM) confirmed that CHP can self-aggregate as spherical particles with 
relatively uniform size.  
 
Figure 1. Structures of polysaccharides that are used in the development of micelle drug delivery. 
Further studies via size exclusion chromatography (SEM) and 1H-NMR provided information 
that one CHP self-aggregate was composed of approximately 13 CHP molecules and that these 
molecules formed a rigid hydrophobic cholesterol core with a relatively mobile pullulan shell. 
More importantly, CHP self-aggregates revealed very high colloidal stability [56]  and have 
since been investigated as a way of protecting proteins from the physiological environment. 
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Studies have shown that CHP self-aggregates can be loaded with insulin with high binding 
constant (K=2x106 M), thereby protecting the entrapped protein from thermal denaturation and 
enzymatic degradation [57, 58].  
More recently, CHP has been further modified to form more complex drug delivery 
systems for higher demand. For example, CHP cross-linked hydrogels with thiol-bearing PEG 
[59] and CHP cross-linked membranes (diameter 6mm, thickness 0.4mm) [60] have been used 
for critical bone defect treatment. Results showed that the crosslinked CHP membrane could 
stimulate and promote bone regeneration with an improved outcome relative to a control, 
collagen membrane [60]. Moreover, the CHP crosslinked hydrogel was successfully used to co-
deliver recombinant human bone morphogenetic protein 2 and fibroblast growth factor 18 (FGF 
18) to induce enhanced bone repair [59]. CHP has also be used to deliver vaccines [61], anti-
tumor agents [62, 63], and wound healing agents with improved solubility and stability. Of note, 
blank CHP, i.e. CHP used in the absence of additional therapeutics, showed a positive effect on 
wound healing compared to control [64].  
Other pullulan based-micelle systems include pullulan acetate [65], poly(DL-lactide-co-
glycolide)-graft pullulan [66], pullulan-g-poly(L-lactide) [67], and pullulan hydrophobic drug 
conjugates, such as pullulan-doxorubicin (DOX) [68] and pullulan-biotin [69]. These systems 
were mainly investigated in regards to chemical synthesis, physicochemical characterization, and 
drug release. To elucidate the potential of these systems for drug delivery, additional studies 
should focus on the interaction of the micelles with cells, tissues, and living systems. 
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Table 1. Names and structures of hydrophobic moieties used in the development of 
polysaccharide-based micelle drug delivery systems. Functional groups used for grafting onto 
polysaccharides are highlighted in red. 
Name Structure References 
Cholesterol 
 
[55, 56, 70] 
Cholic Acid 
 
[71, 72] 
Deoxycholic Acid 
 
[71, 73, 74]  
Poly(lactide) 
 
[67, 75] 
Poly(lactide-co-glycolide) 
 
[66] 
Pluronic 
 
[76] 
Polycaprolactone 
 
[77] 
Stearic Acid 
 
[71] 
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Nanoparticles have been formed by complexing sulfated and aminated derivatives of 
pullulan with oppositely charged chitosan and carrageenan, respectively [78]. These 
nanoparticles had a size of 180-270 nm and were able to associated with a model protein, bovine 
serum albumin (BSA), for eventual use in transmucosal delivery.  
2.2.3.1.2 Cellulose-Based Systems    
Cellulose is the most abundant naturally occurring polysaccharides and its derivatives 
have been widely used in the pharmaceutical field. For example, hydroxypropyl cellulose (HPC) 
was produced by modifying some of the cellulose hydroxyl groups with propylene oxide to 
improve the cellulose solubility and control drug release [79]. To improve the oral delivery of 
hydrophobic drugs, which often have poor bioavailability after administration, Winnik et al. 
further modified HPC with hydrophobic polyoxyethylene hexadecyl (C16) or octadecyl (C18) 
group ester (POE)10 or 20-C16 or 18. With five hydrophobic molecules per HPC chain, the critical 
micelle concentration (CMC) was 65-135 mg/L while with ten hydrophobic chains, the CMC 
dropped to 15-22 mg/L. Cyclosporin A (CyA), a poor water-soluble immunosuppressant, was 
used as a model drug in this study. With lower hydrophobic modification, the maximum loading 
was 0.025 mg CyA/mg micelle, while, as anticipated, with higher modification, the loading 
capacity increased to 0.067 mg CyA/mg micelle. With the same quantity of hydrophobic 
moieties, PEO-C16 provided an improved solubilizing environment for CyA relative to PEO-C18. 
With the encapsulation of CyA, the polymeric micelles size dropped from 78-90 nm to 44-74 
nm. Presumably, the encapsulation of CyA enhances the hydrophobic interactions in the core and 
produces more compact particles. In vitro studies showed HPC-PEO-C16 micellar system had 
high affinity to mucus and could enhance the permeability of entrapped therapeutics across 
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intestine epithelial-Caco-2 cells [80-82]. These studies demonstrated the great potential of HPC-
based micelles for improved oral delivery of hydrophobic molecules.  
Other work has focused on the design and synthesis of cellulose-based micelles; 
however, how these systems can be applied to the field of drug delivery has not yet been 
described. Such systems include HPC-polycaprolactone [83] and cellulose-C15-pyrene micelle. 
Of interest, micelles prepared from cellulose-C15-pyrene with longer cellulose chains (Mw = 
4860 g/mol, number average degree of polymerization (Dn) = 30) were smaller in size (~40.0 
nm, monolayer micelle) relative to those prepared from short chain cellulose (Mw = 2106 g/mol, 
Dn = 13) (~108.8 nm, multilayer micelle) [84]. 
Cellulose has also been used to form gel nanoparticles. Thiolated hydroxyethyl cellulose 
was reacted with tripolyphosphate (TPP) and covalently crosslinked via a disulfide bond 
formation using H2O2 as oxidant. These nanoparticles were 270-360 nm and were able to help 
drug absorption across the mucosa intestines [85]. 
2.2.3.1.3 Dextran-Based Systems 
Dextran is another polysaccharide that has long been used in drug formulation and has 
shown no toxicity [86]. For this reason, Winnik et al. conducted a series of studies on dextran-
based micelles for CyA oral delivery that were nearly identical to the experiments conducted for 
modified CHP. Similar to HPC-PEO-C16, they demonstrated dextran-PEG-C16 had a higher 
loading capacity of CyA relative to dextran-PEG-C18 (0.048 vs. 0.03 mg CyA/ mg micelle), 
although the dextran-based systems yielded higher loading capacities overall compared with the 
HPC-based systems. The size of dextran-PEG-C16 was very small (9 ± 0.3 nm), and CyA loading 
did not significantly affect micelle size (10 ± 0.3 nm). Although not yet tested, this small size 
may limit future in vivo applications. Dextran-PEG-C16 showed no toxicity to Caco-2 cells after 
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4 h of exposure, although free PEG-C16 did inhibit cell growth [87]. Additional in vitro studies 
demonstrated that dextran-PEO-C16 could significantly improved CyA permeability across Caco-
2 cells, although the improvement was lower than that achieved by CyA loaded HPC-PEO-C16 
[82] and, unlike HPC-PEO-C16, dextran-PEO-C16 showed no affinity to mucus [81]. To improve 
the relative low transport efficiency, vitamin B12 was conjugated to the micelle and the vitamin 
B12-dextran-PEO-C16 showed increased transportation of CyA across the Caco-2 monolayer and 
internalization of CyA by Caco-2 cells via the vitamin B12 pathway [88].  
Another highly investigated system is dextran-cholic acid. Cholic acid is one of the major 
bile acids that help to deliver and digest hydrophobic fats in the human small intestine via bile 
acid self-aggregates. Early dextran-cholic acid systems had low stability, as indicated by a high 
CMC value (0.02-0.2 g/ml) [73]. Improved systems were developed by Yuan et al. [89] and Xu 
et al. [90] based on periodate-oxidized dextran which possessed free aldehyde and hydroxyl 
group that were used to form hydrogen bonds to increase system stability. Moreover, the 
micelles served as good depots for the hydrophobic drug indomethacin (~0.299 mg drug/ mg 
micelles) and showed sustained release up to 14 days at acidic and neutral condition. More 
recently, dextran sulfate-cholic acid was investigated to deliver superoxide dismutase (SOD) 
orally. SOD-loaded dextran sulfate-cholic acid had a high stability against the acidic 
environment of the stomach and release in the small intestine was controlled up to 100 hrs. 
Moreover, dextran sulfate-cholic acid facilitated SOD cellular uptake, suggesting that cholic acid 
enhanced the interaction of micelles with the intestinal membrane [72]. Additional dextran-based 
micelles have been synthesized by grafting of polycaprolactone [91], poly (L-lactide) [75], 
polystyrene [92], lauryl group [93], and methyl methacrylate-ethylene glycol dimethacrylate [94] 
to the dextran backbone.  
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Dextran is a FDA-approved material and has long been used as blood plasma expander. 
Due to existing FDA approval, dextran is also an attractive polysaccharides for gel nanoparticles. 
Dextran was chosen by Morgen et al. as the core for a cationic nanoparticle system. The 
nanoparticles were prepared by emulsion method and were injected into the knee joint. Due to 
the positive charge, nanoparticles had enhanced retention after injection by attaching to the 
anionic hyaluronate in the knee joint. Results showed that 70% of nanoparticles was retained in 
the knee joint for 1 week after injection [95]. Another study reported that PEGylated dextran 
nanogels might be a suitable carrier for siRNA as they did not aggregate in human plasma and 
exhibited reduced interactions with blood cells [96]. Dextran-based nanoparticles were also 
developed via a phase separation method with another FDA-approved material, gelatin. These 
nanoparticles were able to carry and release vascular endothelial growth factor (VEGF) in a 
sustained manner to induce angiogenesis [97]. 
2.2.3.1.4 Chitosan-Based Systems 
Chitosan and its derivatives have been the most widely investigated material for drug 
delivery due to the superior properties. To improve delivery of hydrophobic molecules, many 
studies have focused on chitosan-based micelle systems. Most of these core-shell systems were 
developed by modifying chitosan with hydrophobic moieties that include stearic acid [98-102], 
(deoxy)cholic acid [71, 103-105], glucyrrhetinic acid [71, 106], polycaprolactone [77, 107], etc. 
Self-assembly of the modified chitosan can lead to the formation of spherical micelles with a size 
range of 20-500 nm in aqueous solution. Higher hydrophobic moieties modification percentage 
usually gives rise to a smaller micelle diameter due to stronger hydrophobic interactions. Various 
anti-tumor therapeutics such as paclitaxel (PTX) [98, 107-109], doxorubicin [71, 104, 105, 110-
112], and camptothecin [113], have been used as model drugs and encapsulated by chitosan-
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based micelles. The chitosan-based micelles improved the solubility of the hydrophobic drugs 
significantly. Moreover, the micelles showed controlled or sustained release of the hydrophobic 
drugs, and the release rate was tunable by the degree of substitution (DS) of the hydrophobic 
moieties of the micelles. Higher DS usually indicated slower drug release despite insignificant 
changes in the loading efficiency. The therapeutic-loaded micelles showed significantly higher 
toxicity to tumor cells in vitro compared to free drugs due improved drugs internalization. 
Due to the muco/bioadhesive nature of chitosan, chitosan-based micelles have been used 
extensively to improve the oral drug delivery. Evaluated by a Caco-2 cell monolayer, chitosan-
based micelles were demonstrated to inhibit the activity of P-glycoprotein 1 (P-gp) ATPase, 
which, consequently, can inhibit drug efflux and enhance drug permeation [101, 108]. Moreover, 
the chitosan opened the tight junctions between cells and further enhanced drug absorption. The 
chitosan-based micelles were characterized by low CMCs, suggestive of high stability [114] and 
resistance to the harsh environment of the GI tract. In vivo studies showed that N-octyl-O-sulfate 
chitosan can improve the oral bioavailability of TPX by 6 folds compared to the current 
commercially improved formulation-Taxol (Bristol-Myers Squibb, New York, NY) [108]. 
Additionally, chitosan-based micelles were demonstrated to be a relatively safe carrier for oral 
formulation [115]. Chitosan-based micelle systems have also been investigated for applications 
in antivirus [100], anti-thrombogenicity [116], and antiplatelet aggregation [114].   
Chitosan is also a popular material for nanoparticle preparation due to its positive charge. 
Chitosan-based nanoparticles have been fabricated via ionic gelation. For example, surfactant 
Lipoid S100-coated chitosan and glycol chitosan nanoparticles were prepared for systemic 
delivery of low molecule weight heparin (LMWH) via the pulmonary route [117] while 
acyclovir-loaded chitosan nanoparticles [118] and chitosan-dextran sulfate nanoparticles [119] 
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were designed for ocular delivery. These studies showed positive results, including efficient 
delivery of LMWH to the blood stream via pulmonary aerosolization as compared to free 
LMWH and increased residence time of nanoparticles on the ocular surface due to 
mucoadhesion. Another study reported that with addition of a pH-sensitive component, 
methotrexate-loaded chitosan nanoparticles could be developed with greater cytotoxicity in 
acidic tumor environment [120]. Further investigation of chitosan-based nanoparticles as an anti-
tumor delivery system was conducted by W Wei et al [121]. Telomerase reverse transcriptase 
(mTERT) siRNA and paclitaxel (PTX) were co-encapsulated into chitosan nanoparticles via 
Oil/Water/Oil double emulsion method. These nanoparticles were 130-140 nm and had a narrow 
size distribution. siRNA-loaded chitosan nanoparticles showed improved intestinal absorption 
and enhanced tumor cellular uptake. Moreover, chitosan nanoparticles were able to 
simultaneously transport mTERT siRNA and PTX into tumor cells, and this formulation 
achieved synergistic effects that were much more effective than the traditional cocktail therapy.  
2.2.3.1.5 Heparin-Based Micelle Systems 
Heparin is a polysaccharide that has a variety of biological functions, such as 
anticoagulant activity, inhibition of angiogenesis and anti-tumor development [122, 123]. 
Therefore, several studies have focused on heparin-based micelle systems for improved cancer 
treatment. Pluronic block copolymer, composed of hydrophilic poly (ethylene oxide) (PEO) and 
hydrophobic poly (propylene oxide) (PPO) in triblock structure: PEO-PPO-PEO, can improve 
oral availability of hydrophobic drugs by increasing the solubility and permeability while 
inhibiting the activity of P-gp mediated drug efflux and cytochrome P450 metabolism [124, 
125]. To develop oral anti-tumor formulation, heparin-pluronic micelles were developed to 
improve drug absorption. These systems showed proper diameter for tumor accumulation and 
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high loading efficiency for PTX and RNase A, an anti-tumor protein. The therapeutic-loaded 
heparin-pluronic micelles showed 5-6 folds higher permeability through rat intestines relative to 
the clinical PTX formulation, Taxol [76, 126]. Oral availability was also improved by grafting 
deoxycholic acic to low molecular weight heparin. Deoxycholic acid-heparin micelles possessed 
a diameter of 100-200 nm and were absorbed in the small intestine via a bile acid transporter, as 
shown with a nude mouse model [74, 127]. Other micelle systems included heparin-PTX [128, 
129] and heparin-photosensitizer [130].  
2.2.3.1.6 Other polysaccharide-Based Micelle Systems 
One important advantage of polysaccharides is their large diversity of biological functions. 
Advances of polysaccharide research have provided more candidates as potentially functional 
biomaterials. In addition to the most investigated polysaccharides described above, several other 
polysaccharides have also been used to develop micelle systems. Polysialic acid (PSA), in 
particular, is a non-toxic polysaccharide that can be used to protect and increase body circulation 
of therapeutics and has been developed into micelle systems for the delivery to inflamed tissue. 
Using CyA as a model drug, a high loading capacity was achieved and CyA-loaded micelles 
showed high uptake by inflamed synovial fibroblasts (unpublished data) [131]. Alginic acid-PEG 
showed very significant enhancement of hypocalcemia efficacy in rats after intraduodenal 
administration and can improve the oral absorption of salmon calcitionin via alginic acid-PEG 
facilitated transcytosis across Caco-2 cells [132]. Mannan based-micelle systems with high 
stability were developed by grafting cholesterol [133] or hexadecanethiol (C16) [134, 135] to 
mannan. In addition, Modolon et al. have led an investigation of maltoheptaosyl-based micelles 
composed of hydrophilic maltoheptaosyl and hydrophobic peracetylated maltoheptaosyl [136]. 
The all polysaccharide micelles are expected to exhibit better properties and functions.  
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2.2.3.2 Active targeting delivery systems 
2.2.3.2.1 Hyaluronan-Based Systems 
HA is bioactive in that it can bind to the CD44 receptor that is overexpressed in tumor 
and inflammatory tissues. Thus, HA has been investigated as an active targeting agent in drug 
delivery for enhanced efficacy. Most recent HA-based micelle systems have focused on cancer 
treatment with DOX [137-140], PTX [141-143], siRNA [144], and curcumin [145]. These 
systems possessed high physiological stability and a diameter range of 100-200 nm, which is 
expected to facilitate passive accumulation of the micelles in the tumor. HA-based micelles 
showed significantly higher cellular uptake by a CD44 overexpressed cancer cell line compared 
to that of CD44 negative cell line, NIH3T3 [138]. Moreover, by blocking the CD44 receptor with 
free HA molecules, cellular uptake of HA-based micelles was significantly decreased [137, 139]. 
Therefore, HA-based micelle systems were demonstrated as potential systems for improved drug 
efficacy via CD44-mediated endocytosis. To further improve targeting, folic acid, another active 
targeting agent was conjugated to HA and higher cellular uptake was observed with folic acid-
HA-octadecyl group compare to that of HA-octadecyl group [142]. However, due to the high 
affinity of HA to liver sinusodidal endothelial cells that have another HA receptors (HARE), 
HA-based micelles have a high propensity for accumulation in the liver after systemic 
administration. To improve this, PEG was conjugated to HA-5 beta-cholanic acid and liver 
accumulation of micelles was significantly suppressed, while the tumor accumulation was 
increased to 1.6 folds. Intravital tumor imaging also confirmed PEG-HA-5 beta-cholanic acid 
had rapid extravasation into tumor tissue [146].  
In addition to sufaced-modified micelles, HA-based nanoparticles have been widely 
investigated for anti-tumor delivery [147], ocular delivery [148, 149], and transmucosal delivery 
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[150]. HA-based nanoparticles could be formed by reaction with chitosan or its derivatives. The 
size of HA-chitosan nanoparticles was tunable between 300-600 nm by varying HA: chitosan 
ratio. These nanoparticles showed an efficient loading of both bovine serum albumin 
(hydrophilic molecule) and cyclosporine A (hydrophobic molecule) [150]. Additionally, 
significantly better tolerance of cisplatin-loaded HA-chitosan nanoparticles was reported 
compared to cisplatin alone during tumor treatment for mice [147]. Moreover, plasmid DNA-
loaded HA-chitosan nanoparticles provided high transfection levels (up to 15% of cells were 
transfected) to cornea and conjunctiva cells via hyaluronan receptor CD44-mediated fluid 
endocytosis [148, 149].  
2.2.3.2.2 Active Targeting Agents 
Micelles and nanoparticles with proper size, charge, and shape facilitate improved 
delivery. However, this may not be enough because of the defenses of human body. To enhance 
target site accumulation and uptake, additional targeting agents are often incorporated into the 
micelle systems. Active targeting agents used in polysaccharide-based micelles and nanoparticles 
can be divided into three categories: peptides, small molecules, and polysaccharides. Peptides 
include octreotide targeting for the somatostatin receptors on tumor cells [104, 151], the A54 
hepatocarcinoma binding peptide [102], and Arg-Gly-Asp (RGD) containing peptide for αvβ3 and 
αvβ5 integrins [152, 153]. Small molecules include glycyrrhetinic acid, a liver targeting ligand 
[71, 106], vitamin E succinate-specific toxicity to tumor cells [109], and folic acid with a high 
affinity to the folate receptor overexpressed on tumor cells [98, 103, 130, 142, 154-156]. 
Through peptide and small molecule conjugation, micelle systems have shown higher tumor 
accumulation and cellular uptake relative to blank micelles. Moreover, polysaccharides 
themselves can act as active targeting agents due to their bioactivity. As described above, HA 
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has a high affinity to the HA receptor on the liver sinusoidal endothelial cells and the CD44 
receptor that is overexpressed on the tumor cells and inflamed synovial fibroblast. Therefore, HA 
has been highly investigated as an active targeting agent to tumor tissue or liver with many 
micelle systems. In addition, heparin-based micelles have demonstrated enhanced inhibition of 
tumor growth and angiogenesis, while cellulose, chitosan, and pullulan-based systems promoted 
drug absorption across the small intestine due to enhanced mucoadhesion.  
2.2.3.3 Multifunctional delivery systems 
2.2.3.3.1 Stealth Coating 
To achieve high therapeutic efficacy, therapeutics must have a long circulation time in 
the body to ensure that an effective concentration at the target site is achieved. However, free 
drugs and many carrier systems bind to plasma proteins and are rapidly cleared. To minimize 
clearance and prolong the circulation, PEG has been conjugated or coated to many micelle 
systems. For example, studies have shown that PEG protected octyl-succinyl-chitosan from 
plasma protein absorption [151] and that PEG modification could prolong HA-ceramide 
circulation [138]. Moreover, PEG could inhibit liver uptake of HA-conjugated micelles, thereby 
increasing the systemic circulation [146].  
Despite the demonstrable improvements relative to unmodified systems, there are 
potential drawbacks of PEG usage, such as the non-biodegradable PEG backbone, continuous 
accumulation in the body, and possible induction of an immune response [48, 157, 158]. In 
addition, the PEG coating may interfere with cellular uptake of drugs because PEG has been 
reported to reduce drug-cell interaction and to hinder the drug release from carrier systems [159-
161]. As an alternative, other molecules that are hydrophilic, biodegradable, non-toxic, and non-
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immunogenic have been sought. For example, polysialic acid (PSA) meets all of the latter 
criteria and, of equal importance, PSA has no known receptors in the human body, suggesting 
the possibility for further improvement in circulatory stability. Gregoriadis et al. have 
investigated a series of PSA-protein conjugate and shown prolonged circulation of insulin [6], 
asparaginase [4, 5], and catalase [2, 3]. Recently, Bader et al. synthesized PSA-based micelle 
systems for future applications in drug delivery[131].  
In another study, a cationic polysaccharide nanoparticles showed stealth behavior after 
loading of an anionic molecule-dipalmitoyl phosphatidyl glycerol (DG) and a polyanionic 
molecule-BSA. The authors reported DG and BSA-loaded nanoparticles had comparable anti-
adhesive property with long chain PEG because of neutralization of surface charge by DG and 
BSA [162].  
2.2.3.3.2 Stimuli-Sensitive Systems 
Stimuli-sensitive systems can provide more controllable drug delivery with better 
efficacy. Based on the solution to gel phase transition properties of polymer, thermo-sensitive 
systems have been developed. For example, Kim et al. reported an injectable, low molecular 
weight methylcellulose-pluronic gel/micelle system that was a solution at 25°C and gel at 
physiological temperature. The solution phase is expected to facilitate injection, while the gel 
phase was demonstrated to sustain drug release for approximately 3 weeks [163]. Likewise, a 
pullulan-based micelle system contained thermo-sensitive poly (L-lactide) that gelled at 42°C. 
Gelation induced additional anti-cancer drug release and, consequently, better inhibition of 
tumor cell growth [67].  
pH-sensitive system have also been developed. Several intracellular structures, 
particularly endosomes and lysosomes, are characterized by a low pH. In addition, tumor and 
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inflamed tissue often possess a pH that is slightly lower than normal (6.5-7.2). Thus, by 
developing pH-sensitive systems, premature leakage of drugs from the micelles can be reduced 
and maximum drug release can be achieved at the target site. To date, almost all such systems 
have been developed for tumor treatment. Selective release at the tumor site is accomplished by 
incorporating various moieties with hydrophobic and electronic interactions that change with pH 
[105, 139, 151, 164, 165].  
 Additional, chitosan-heparin nanoparticle system was stable in gastric acid of the gastric 
lumen and was able to adhere and infiltrate into the mucus layer of the gastric tract while 
unstable in neutral pH [166]. This system could be used to protect drugs from digestion of gastric 
tract and to release drug in target sites. 
Chemical signals can also provide a method for site-specific drug release from micelles. 
For instance, glutathione (GSH) concentration in tumor cells is 4 folds higher than in mammalian 
cells and 3 orders higher than in plasma. The high concentration of GSH in tumor cells can 
attack the unsaturated and disulfide bonds that exist within macromolecules and facilitate 
degradation or other structural changes. Therefore, polysaccharide-based micelle systems that 
contain these sensitive bonds (so called “redox (reduction-oxidation)-sensitive systems”) have 
been investigated for tumor targeting and intracellular efficacy enhancement. As an example, a 
negligible amount of pro-drug was released from carboxymethyl chitosan-based micelles without 
GSH and at low concentrations of GSH; however, 75% of the conjugated drug was released with 
the presence of GSH at 20 mM [167, 168]. Likewise, Li et al. led a study of redox-sensitive 
micelles, specifically HA-deoxycholic acid conjugates that were loaded with PTX for tumor 
targeting. At GSH 20 mM, the micelles underwent fast disassemble and released the PTX into 
the cancer cells. The redox-sensitive, PTX-loaded HA-based micelles showed higher tumor 
  
27 
targeting capacity and more potent efficacy towards cancer cells compared to an insensitive 
control [141]. Heparin-pluronic-based micelles that are responsive to high GSH concentrations 
have also been developed [152].  
Although not well explored, evidence suggests that photosensitive polysaccharide-based 
micelles may serve as functional, smart materials in drug delivery. Modification of pullulan with 
spiropyrane yielded hydrophobized polysaccharide that self-assembled into micelles. The 
amphiphilicity of the spiropyrane core was modulated through irradiation with visible light, 
which consequently impacted the interaction and release of associated proteins [105, 107]. 
Similarly, release of model compounds from micelles formed from azobenzene-dextran was 
controlled through exposure to UV-Vis light [169].  
2.3 Drug delivery systems for the treatment of rheumatoid arthritis 
(RA)  
2.3.1 RA  
RA is a chronic autoimmune disease with a general prevalence around 1% [170]. RA 
patients experience chronic joint pain and swollenness in the initial stage and cartilage 
destruction and bone absorption in the late stage. In severe RA cases, irreversible impair occurs 
to multiple organs and the life span is shortened [171, 172]. Despite much research, causes of 
RA are unclear. Current understandings are that RA may be initiated by an interplay of genetic 
factors, sex hormones, infectious agents, and/or immune activating agents [173]. RA joints are 
characterized by inflammation, synovial hyperplasia, and abundant immature blood vessel 
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formation. Common treatments are disease-modified anti-rheumatic drugs (DMARDs), non-
steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids (GCs), and biological agents. 
These treatments are all associated with severe side effects, including infection, osteoporosis, 
hypertension, lung fibrosis, liver damage, and kidney failure. These adverse consequences of the 
drugs are caused by poor affinity to the inflamed joint, metabolism in the liver, and quick 
excretion from the kidney. In clinical practice, rheumatologists usually prescribe combinations of 
these treatments, which may increase the risk of side effects. 
2.3.2 Drug Delivery for RA 
The leaky vasculature can be exploited for delivery of drug-loaded nanocarriers. 
Encapsulation endows the drugs with an increased size from 1-10 nm to 50-150 nm. The larger 
size increases the chance of accumulation in the diseased tissue and reduces the likelihood of 
clearance by RES. Moreover, the RA synovium undergoes a series of abnormal metabolic 
changes, including over-expression of certain cell surface proteins and receptors that can be used 
as targets for delivery. Drug delivery techniques will not change the structure of drugs, however, 
in vivo behavior will be modified in hopes of improving efficacy of treatment and minimizing 
side effects.  
To treat RA, several macromolecular conjugate formulations have been developed. For 
example, human bovine serum-MTX conjugates showed increased accumulation in the inflamed 
paw of arthritic mice and could suppress secretion of pro-inflammatory proteins [174, 175]. 
Another conjugate was based on pH-sensitive N-(2-hydroxypropyl) methacrylamide (HPMA) 
copolymer and dexamethasone (DM) [176]. When HPMA-DM was administrated systemically 
in an adjuvant-induce arthritis rat model, HPMA-DM showed long lasting anti-inflammatory 
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effect relative to free DM. Better bone and cartilage preservation of rats were also observed.  In 
addition, maximum release of DM was achieved in the acidic arthritic joints.  
Liposomes are the most frequently used drug carriers and some liposomal formulations 
have been approved for marketing [177, 178]. MTX-loaded liposomes showed a prolonged 
retention time in the joint [179, 180] and liposomal corticosteroids were effective as a 10-fold 
higher dose of free drug in rat adjuvant-induced arthritis (AIA) and murine collagen-induced 
arthritis (CIA) [181]. In addition, PEGylated liposomes have also shown prolonged body 
circulation and tissue retention [182-184]. However, further studies have shown that liposomes 
possessed low physicochemical stability, a high likelihood for drug leakage, and a propensity in 
liver and spleen [181, 185]. More stable carriers are needed to achieve the goal of safe and 
targeted delivery. 
Nanoparticles have good stability and a high drug loading. To date, investigators have 
used nanoparticles to deliver anti-rheumatic drugs, and positive results were reported, including 
reduced inflammation, improved efficacy, and higher specificity. Examples of nanoparticle 
systems included betamethasone sodium phosphate loaded PLGA nanoparticles,[186] IL-1 
receptor antagonist (IL-1Ra) loaded chitosan-folate nanoparticles [187], anionic photosensitizers 
loaded chitosan-hyaluronate nanoparticles [188], and sterically stabilized micelles decorated with 
vasoactive intestinal peptide[189].  
The future of drug delivery for RA will be passively targeted drug carriers with active 
targeting agents based on stealth and stimuli-sensitive materials to achieve optimal drug delivery 
based on the needs of diseases.  
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2.5 Summary  
Drug delivery has provided a method to optimize drug administration and disease 
treatment. However, the demand for new, innovative drug delivery and technology remains. 
Ideal drug carriers act to protect drugs from degradation and clearance, while allowing drugs to 
arrive and release at target sites. Polysaccharides are good candidates for drug carriers because of 
their good solubility, high biocompatibility, low immunogenicity, stealth properties, muco-
adhesion, ease of modification, etc. Although much research of polysaccharide-based drug 
delivery systems has initiated, advanced multifunctional systems are needed due to the 
complexity of diseases and the many barriers in human body. RA was selected as the primary 
disease model for our studies based on the paucity of research on RA drug delivery. This chapter 
has highlighted the advantages of polysaccharide as the basis for drug delivery systems and has 
provided an overview of the polysaccharide-based micelles and nanoparticles that have been 
developed to date. In subsequent chapters, we will describe the work we have done in the field of 
polysaccharide-based nanoparticles and micelles for RA treatment. 
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Chapter 3 Polysialic Acid-Based Micelles for 
Encapsulation of Hydrophobic Drugs 
Despite improvements relative to unmodified counterparts, poly (ethylene glycol) (PEG) 
conjugation may not be the ideal solution for improving circulatory stability of current 
nanoparticle carriers or free drugs. Polysialic acid (PSA), a natural polymer for which the body 
possesses no receptors, has been conjugated directly to biologically active molecules to prevent 
premature clearance; however, this concept has not yet been applied to nanoparticle drug carrier 
systems. In the current study, PSA was modified with a long-chain hydrocarbon through reaction 
of the carboxylic acid side groups with N-decylamine (DA). The resultant PSA-DA conjugates 
self-assembled into micelles for encapsulation of hydrophobic drug molecules, as demonstrated 
with Cyclosporine A. Cytotoxicty was dependent on the degree of substitution with DA. On the 
basis of size and zeta potential, the micelles are capable of passively targeting diseased regions, 
such as cancer and inflammatory tissue. Further investigations are necessary to explore whether 
the PSA-based micelles possess stealth properties similar to those of PEG and to establish in 
vitro and in vivo efficacy. 
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3.1 Introduction 
Poly (ethylene glycol) (PEG) conjugation has customarily been used to improve the 
circulatory stability of free drugs, as well as nanosized drug delivery systems [190-194]. 
However, despite improvements relative to unmodified counterparts, PEG may not be the ideal 
solution for improving circulatory stability. There is evidence of continued uptake by the 
reticuloendothelial system (RES), and concerns remain about the non-degradable nature of the 
synthetic polymer as well as potential immunogenicity, as indicated by observation of 
complement activation and the formation of anti-PEG antibodies following administration [157, 
158]. 
Polysialic acid (PSA), a natural, biodegradable carbohydrate polymer primarily 
composed of R-2, 8-linked 5-N-glycoly-neuraminic acid (Neu5Ac) is a relatively unexplored 
material for the prevention of premature clearance. PSA has been found on the surface of both 
mammalian and bacterial cells. In mammalian tissue, PSA is a post-translational modification of 
neural cell adhesion molecule (NCAM), and the large, negatively charged chains are thought to 
act via a steric mechanism to promote neural plasticity by reducing cell-cell interactions, thereby 
permitting cell migration. PSA is highly expressed by embryonic neural tissue and is associated 
with axon path finding and targeting as well as cell migration and muscle development. Most 
tissues in adults are not associated with PSA; however, patterns of expression are still observed 
in brain tissue with known plasticity and in damaged neural tissue [195]. Cancer cells also 
express PSA, and the polysaccharide is thought to play a role in tumor growth and metastasis 
[196]. Bacteria express PSA with chemical and immunological properties identical to those of 
mammalian-produced PSA; therefore, PSA is used to mask the antigenicity of invading 
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organisms from the immune system of the host [195, 197]. Furthermore, PSA-specific receptors 
have not been identified in the body [1, 48, 198, 199]. Given the lack of immunogenicity, in 
conjunction with the absence of receptors and high hydrophilicity, PSA should confer stealth 
properties to associated molecules. 
The potential for PSA to improve the circulatory stability of existing therapeutics was 
initially recognized by Gregoriadis, et al. in a series of studies [1, 5, 48, 198, 199]. Gregoriadis 
proposed that the hydrophilic polymer chains would lead to the formation of a “watery cloud” 
that would thereby prevent interaction with proteins and cells of the immune system. As a result, 
a protective envelope would effectively be formed around drug molecules covalently linked to 
PSA, thus masking the therapeutic molecule and preserving structure and function. Furthermore, 
the large size (∼30 kDa) and anionic charge of PSA would permit the drug molecule to reside in 
the body for longer periods of time by reducing urinary excretion and hepatic uptake [1, 48, 198, 
199]. Studies on pharmacokinetics have revealed that a high molecular weight and a weakly 
anionic charge are typically indicative of macromolecules that will form the basis of good 
polymer-based drug carrier systems [200]. 
Initial studies on polysilylation demonstrated that asparaginase half-lives can be 
significantly extended. Furthermore, native asparagines elicited an immune response, whereas 
PSA conjugated to asparaginase did not, suggesting that PSA can suppress antigenicity [5]. 
Conjugation to reduce clearance has been extended to other biologically active compounds [201-
203], and polysialylated derivatives of insulin [6], granulocyte colony stimulating factor (GCSF), 
and interferon R-2b (IFN-α2β) are currently in the preclinical stages of drug development for the 
treatment of type II diabetes, neutropenia, and hepatitis C, respectively. 
Although in-depth studies on how PSA acts to prevent uptake by the RES have not yet 
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been conducted, the “watery cloud” that Gregoriadis refers to presumably functions in a manner 
similar to the fixed aqueous layer of PEGylated liposomes. In addition to providing a physical 
barrier, mechanistic investigations have revealed that PEG chains interact with surrounding 
water molecules to form an aqueous layer that prevents attraction and binding of serum proteins 
[204]. An increase in the fixed aqueous layer thickness of PEGylated liposomes has been 
associated with a reduction in uptake by macrophages [205] and an increase in the efficacy of the 
associated therapeutic [204]. 
Despite success with conjugation, the concept of using PSA in drug delivery for targeted 
drug delivery has yet to be extended to nanoparticle carrier systems. In this study, we modified 
PSA with long-chain alkyl amines, and the resultant compounds self- assembled to form 
polymeric micelles. Cytotoxicity was assessed using the MH7A rheumatoid arthritis synovial 
fibroblast cell line via a WST-8 assay. The ability of the micelles to encapsulate hydrophobic 
therapeutics was demonstrated with Cyclosporine A. The choices in cell line and therapeutic 
were based on future intended applications of this work toward targeted drug delivery for 
treatment of rheumatoid arthritis. 
3.2 Materials and Methods 
3.2.1 Material 
Colominic acid sodium salt (PSA, isolated from E. coli) was obtained from Nacalai USA 
(San Diego, CA). The marketed molecular weight of 30 kDa was confirmed via HPLC. N-(3-
Dimethyl- aminopropyl)-N′-ethylcarbodiimide (EDC), N-hydroxysuccinimide (NHS), 
decylamine (DA), and acetonitrile were purchased from Sigma-Aldrich. (St. Louis, MO) and 
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used as received. The MH7A synovial fibroblast cell line was provided by the Riken BRC 
through the National Bio-Resource Project of the MEXT, Japan. RPMI-1640, D-PBS, HEPES, 
L-glutamine, fetal bovine serum (FBS), and penicillin-streptomycin were obtained from Lonza 
(Allendale, NJ). 
3.2.2 Preparation of Decylamine-Modified Polysialic Acid (PSA-DA) Micelle 
The synthesis of DA-modified polysialic acid (PSA-DA) is depicted in figure 2. To 
obtain a 50-60% degree of substitution (DS) of Neu5Ac monomers, EDC (23.0 mg, 0.12 mmol) 
and NHS (13.8 mg, 0.12 mmol) were added to PSA (60 mg, 0.19 mmol repeating units) 
dissolved in 10 mL of DI water. After stirring at room temperature for 30 min, DA (18.8 mg, 
0.12 mmol) was added, and the reaction was allowed to proceed overnight. The solution was 
dialyzed against DI water for 24 h (MWCO ≈ 5 kDa) and lyophilized to yield the desired PSA-
DA product. Proton (1H) NMR (Bruker 300) showed formation of the desired amide bond 
between DA and PSA as well as an N-acylurea side-product resultant from rearrangement of the 
O- acylisourea intermediate. PSA-DA was also prepared with degrees of substitution of 15-25, 
30-40, and 90-100% following the same protocol with appropriate amounts of EDC, NHS, and 
DA relative to Neu5Ac monomers. To generate a control for PSA-DA in cytotoxicity studies, we 
modified PSA with EDC using the above procedure, omitting the addition of DA. 
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Figure 2. Synthesis of Decylamine modified Polysialic acid (PSA) 
3.2.3 Characterization of PSA-DA Micelle 
3.2.3.1 Size and Zeta Potential 
Particle size, size distribution, and zeta potential of the PSA-DA micelles, both with and 
without encapsulated CyA, were obtained with a Zetasizer Nano ZS (Malvern Instruments). 
Aqueous samples were prepared at a concentration of 10 mg/mL in ultrapure water and used 
without filtration. For dynamic light scattering measurements, the temperature was set to 25 °C 
and the scattered light was detected at an angle of 173°. Particle sizes for each DS are reported as 
the mean of the sizes derived from the number distributions plus/ minus the standard deviation, 
whereas size distributions are reported as the mean plus/minus the standard deviation of the 
polydispersity indices (PDIs) (N = 6-9 for each DS). To ensure that sizes and zeta potentials 
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remained the same at an elevated temperature, we also characterized PSA-DA with a DS of 50-
60% at 37 °C, both with and without encapsulated CyA. To observe the impact of dilution, we 
also made size measurements on CyA-loaded PSA-DA micelles (DS 50-60%) at concentrations 
of 1 and 0.1 mg/mL. 
3.2.3.2 Critical Micelle Concentration 
The critical micelle concentrations (CMCs) for PSA-DA prepared with various degrees 
of substitution were determined with steady-state fluorescence measurements using pyrene as a 
probe. We added 8.1 µL of 1.24 × 10-4 M pyrene stock solution in acetone to nine individual 
vials, and the acetone was allowed to evaporate. To each vial was added 5 mL of aqueous 
solutions of PSA-DA with concentrations ranging from 0.01 µg/mL to 1.0 mg/ mL. The 
solutions were sonicated for 30 min at room temperature and heated with shaking at 65 °C for 4 
h to permit equilibration. After cooling in the dark overnight, excitation spectra were recorded at 
an emission wavelength of 390 nm with a QuantaMaster-4/2005 sensitivity- enhanced (QM-
4/2005 SE, Photon Technology International) fluores- cence spectrophotometer. The CMCs were 
determined from plots of I339/I337 versus log concentration via the intersection of the tangent of 
the inflection point with the horizontal tangent through low concentration points [206]. 
3.2.3.3 Atomic Force Microscopy 
The morphology of the PSA-DA micelles prepared with a DS of 50-60%, with and 
without encapsulated CyA, was observed using atomic force microscopy (AFM). A drop of 
aqueous sample was placed on a glass coverslip and allowed to dry in a vacuum desiccator for 
several hours. Images were obtained with a Nanoscope III AFM (Veeco Instruments) in contact 
mode. 
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3.2.4 Hydrophobic Drug Encapsulation 
Hydrophobic cyclosporine A (CyA) was encapsulated within the PSA-DA micelles using 
a cosolvent evaporation method [207]. A stock solution of CyA in acetone was prepared at a 
concentration of 6 mg/mL. We added 167, 334, 501, and 668 µL of CyA stock solution to vials 
containing 10 mg of PSA-DA dissolved in 1 mL of DI water to yield CyA weight percentages of 
10, 20, 30, and 40 relative to PSA-DA. The solutions were stirred gently at room temperature for 
4 h to permit encapsulation of CyA within PSA-DA micelles. We removed acetone by heating at 
65 °C for 15 min such that the solution volume was returned to the original volume (1 mL), and 
insoluble non-encapsulated CyA was separated by centrifugation at 11 000g for 5 min. 
High-performance liquid chromatography (HPLC) was used to assess the loading 
capacity and encapsulation efficiency of the PSA-DA micelles. Following an established 
protocol, we added 600 µL of acetonitrile to a 200 µL aliquot of CyA-loaded micelles in water, 
prepared as described above, to release encapsulated drug [208]. The resultant solutions were 
assayed for CyA with a Prominence UFLC (Shimadzu Corporation) equipped with a Shim-pack 
XR-ODS reversed-phase column (3 mm i.d. × 50 mm) and a dual-wavelength UV-vis detector. 
A mobile phase of 3:1 acetonitrile/water was used with a flow rate of 0.5 mL/min. The column 
temperature and detection wavelength were set to 40 °C and 210 nm, respectively. 100 µL was 
injected for each sample, and CyA was observed as a broad peak centered at an elution time of 
4.2 min. The area under the peak was determined following Loess smoothing using PeakFit 4.2 
software. A calibration curve was generated from a five- parameter logistic model using standard 
solutions prepared in 3:1 acetonitrile/water with CyA concentrations that ranged from to 6.25 to 
100 µg/mL. Following IUPAC guidelines, the limit of detection (LOD) was calculated from six 
blank samples as the mean plus three times the standard deviation, whereas the limit of 
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quantification (LOQ) was taken as the mean plus ten times the standard deviation [209]. Loading 
capacity and encapsulation efficiency of CyA-loaded PSA-DA micelles were calculated as 
LC = 
!!"#!!"#$%$!!"#!!"         (3.1) 
LE = 
!!"#!!"#$%$!!"#!!""#"   ×  100     (3.2) 
where WCyA-loaded is the amount of CyA incorporated into the micelles, as determined using the 
calibration curve, WPSA-DA is the amount of PSA-DA used, and WCyA-added is the amount of CyA 
added to the PSA-DA solution. 
3.2.5 PSA-DA Micelle Stability  
3.2.5.1 Freeze-Drying/Resuspension 
CyA-loaded PSA-DA micelles (DS 50-60%), prepared as described above with 10 wt % 
CyA relative to PSA-DA, were frozen in a -80 °C freezer without the addition of a 
cryopreservative and lyophilized with a freeze-dryer. Samples were reconstituted by simple 
shaking after the addition of DI water. The reconstituted micelle solutions were immediately 
characterized by AFM and dynamic light scattering. 
3.2.5.2 Mechanical and Thermal Stability 
CyA-loaded PSA-DA micelles (DS 50-60%), prepared as described above with 10 wt % 
CyA relative to PSA-DA, were tested for mechanical and thermal stability. Samples for 
mechanical stability testing were immediately subjected to 5 additional minutes of centrifugation 
at 11 000g for 5 min, whereas samples for thermal stability testing were incubated at 37 °C with 
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shaking for 1 week. Upon completion of the thermal stability test, non-encapsulated CyA was 
removed by centrifugation. CyA content was assessed immediately following both tests via 
HPLC, as described above. 
3.2.6 Cytotoxicity of PSA-DA 
Cytotoxicity of the PSA-DA micelles was evaluated via WST-8 assay (Cayman Chemical 
Company) using the MH7A synovial fibroblast cell line. Reduction of the WST-8 tetrazolium 
salt by NADH produced within the mitochondria yields formazan dye, which can be quantified 
by measuring the absorbance at 450 nm. Cells were seeded into a 96-well cell culture plate at a 
density of ∼5000 cells per well and cultured for 24 h. PSA-DA of various DS values was added 
at concentrations ranging from 15.6 to 500 µg/mL, and the cultures were maintained at 37 °C, 
5% CO2. After 24 h, 10 µL of WST-8 solution was added to each well, and incubation was 
continued for 90 min. The absorbance at 450 nm was measured with a Synergy 2 multimode 
microplate reader (BioTek Instruments). The cytotoxicity of CyA alone, PSA reacted only with 
EDC/NHS, and CyA-loaded PSA-DA (DS 50-60%) was also evaluated over an identical range 
of concentrations following the above procedure. CyA-loaded PSA-DA was used after freeze-
drying. As a control, MH7A synovial fibroblasts were grown in media without any additives. For 
each DS, the absorbance relative to the control was plotted versus the concentration, and the data 
were fit to a five-parameter logistic to determine the IC50. 
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3.3 Results and Discussions 
3.3.1 Synthesis of PSA-DA Micelle 
PSA is a natural, biodegradable polymer that may be used in lieu of poly (ethylene 
glycol) to improve the circulatory stability of free drugs and nanoparticle drug carriers. 
Polymeric micelles for hydrophobic drug encapsulation were prepared from DA-modified 
polysialic acid (PSA-DA), as depicted in figure 2. NHS was necessary to obtain the expected 
degrees of substitution (DS) of Neu5Ac monomers, as determined by 1H NMR. DS was 
calculated from the relative intensity of the terminal methyl (-CH3) peak in DA to the acetyl (-
NHCOCH3) peak in PSA. The reaction also yielded the N-acylurea side product resultant from 
the rearrangement of the O-acylisourea intermediate. As assessed by the N-dimethyl (-N(CH3)2) 
peak, 20-25% of the Neu5Ac monomers were modified with the N-acylurea side product when 
the DS for DA was between 10 and 60% (Figure 32, Figure 33). A survey of the literature 
demonstrated that the N-acylurea side product is typically obtained when EDC/NHS is used in 
the synthesis of polysaccharide-based bioconjugates and hydrogels [210-214]. Furthermore, the 
N-acylurea group has been shown to be nontoxic toward cells [210, 214, 215], and, when 
released from hyaluronan- based hydrogels, the urea has been shown to exhibit anti-
inflammatory properties [216, 217]. Therefore, the presence of N-acylurea does not preclude the 
use of PSA-DA in drug delivery, and characterization was continued. 
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3.3.2 Characterization of PSA-DA Micelle 
Pyrene was used as a fluorescent probe to evaluate the CMC for PSA-DA. As pyrene 
partitions between the hydrophobic environment of the micelle core and the hydrophilic aqueous 
environment, there is a shift in the excitation spectrum, as well as a corresponding change in the 
relative intensities of the vibrational bands. Only the shift in the excitation spectrum yields an 
unambiguous assignment of the CMC; therefore, plots of I339/I337 versus concentration were 
constructed [206]. CMCs for each DS range were determined using the intersection of the 
tangent of the inflection point with the horizontal tangent of the low concentration points. 
Representative plots for PSA-DA with a DS of 50-60% As expected, on the basis of the results 
obtained via HPLC and particle size analysis that suggest an increase in micelle stability with 
higher DS, the CMC was found to decrease with increasing DS (Table 2). A clear CMC could 
not be identified for PSA-DA with a DS of 15-25%. Although the CMCs were higher than those 
observed for the well-known PEG-PCL system, the values were again consistent with dextran 
modified with PEG and hydrophobic alkyl chains (Figure 2) [82, 87, 88]. 
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Figure 3. Excitation spectra for pyrene in a range of concentration (mg.ml) of PSA-DA (A) and a 
plot showing the change in I338/I336 as the concentration of PSA-DA (mg/ml) is increased (B) 
Table 2. Characteristics of PSA-DA micelle with various DS values 
DS CMC 
(µg/ml) 
Size without 
CyA (nm) 
PDI without CyA  Size with 
CyA (nm) 
PDI with CyA 
15-25% - 25.5 ± 7.4 0.40 ± 0.07 41.9 ± 14.1* 0.49 ± 0.12 
30-40% 99.6  54.7 ±  25.4 0.31 ± 0.01 90.1 ± 46.2 0.26 ± 0.06 
50-60% 73.0  91.2  ± 5.4 0.24 ±  0.05 107.6 ± 16.2* 0.21 ± 0.02 
90-100% 53.9  138.9  ± 4.0 0.15 ±  0.02 151.2 ± 18.8 0.18 ± 0.03 
*Significantly different than the size without CyA (p < 0.05) as determined by Student’s t test.  
3.3.3 Hydrophobic Drug Encapsulation 
Cyclosporine A (CyA) is currently used as an immunosuppressant to prevent organ 
rejection following transplantation and is regularly used as a disease-modifying anti-rheumatic 
drug (DMARD) in the treatment of rheumatoid arthritis [218]. The immunosuppressive effect of 
CyA appears to be largely a result of inhibition of T-cell activation [218]; however, CyA has also 
been linked to a reduction in the secretion of pro-inflammatory mediators by inflammatory cells 
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[219, 220]. Our long-term goal is to use polysaccharide-based micelles for targeted drug delivery 
of DMARDs to inflamed joint tissue; therefore, CyA was used to demonstrate the propensity of 
PSA-DA to encapsulate hydrophobic drugs. The bioavailability of CyA is highly variable 
because of poor solubility and side effects, particularly nephrotoxicity, result from nonspecific 
delivery, in combination with unfavorable pharmacokinetics [221]. Encapsulation within PSA-
DA-based micelles should increase the efficacy of the drug by increasing the solubility, and 
therefore the bioavailability, while simultaneously providing a new mode of delivery that 
minimizes organ toxicity by facilitating targeting of diseased regions. 
HPLC was used to assess the amount of CyA loaded into the PSA-DA-based micelles. 
Following release from the PSA-DA micelles by dissolution with acetonitrile, the amount of 
encapsulated CyA was quantified based on a calibration curve generated from CyA standards 
(6.25-100 µg/mL). Following IUPAC guidelines [209], the LOD was found to be 3.78 µg/mL, 
whereas the LOQ was found to be 5.75 µg/mL. A high initial concentration of PSA-DA (10 
mg/mL) was used to ensure that the amount of CyA encapsulated fell within the limits of the 
calibration curve for all loading conditions. 
PSA-DA with DS values of 50-60 and 90-100% were found to encapsulate CyA 
successfully with loading capacities of 0.0241 and 0.0268 and encapsulation efficiencies of 23.6 
and 26.8%, respectively, when CyA was added at 10 wt % relative to PSA-DA. In contrast, DS 
values of 15-25 and 30-40% yielded low loading capacities (≤0.013). PSA-DA with a DS of 50-
60% was used to explore further the effect of the wt % of CyA added on the loading capacity and 
encapsulation efficiency (Table 3). A maximum loading capacity of 0.0350 with a corresponding 
loading efficiency of 11.7% was achieved, with the addition of 30 wt % CyA. Unexpectedly, the 
loading capacity decreased at 40 wt % CyA. The latter occurrence has been observed for 
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hydrophobic drug encapsulation within chitosan-based micelles and can be attributed to 
precipitation of the drug from the aqueous phase concurrent with drug encapsulation [222]. The 
values for loading capacity and encapsulation efficiency determined for CyA in PSA-DA with 
DS values of 50-60 and 90-100% were less than those established for the common PEG-PCL 
micelle system [223] but nearly identical to those found for dextran modified with PEG and 
long-chain hydrocarbons (C18 and C19) [82, 87, 88]. 
Table 3. Loading capacity and encapsulation efficiency of CyA-loaded PSA-DA micelles with a 
DS of 50-60% 
Wt. % of CyA* Loading Capacity  
(mg CyA/mg PSA-DA) 
Encapsulation Efficiency 
(%) 
10 0.0241 ± 0.0017 23.6 ± 2.2 
20 0.0301 ± 0.0007 15.0 ± 0.3 
30 0.0350 ± 0.0004 11.7 ± 0.1 
40 0.0294 ± 0.0003 7.3 ± 0.1 
*Wt.% of CyA refers to the weight percent of CyA added relative to the weight of PSA-DA. 
 
3.3.4 PSA-DA Micelle Stability 
To assess micelle stability, we re-evaluated the amount of encapsulated CyA within PSA-
DA micelles (DS 50-60%) following mechanical and thermal testing. Additional centrifugation 
at high speed did not significantly affect the loading capacity or encapsulation efficiency. 
However, after the drug-loaded PSA-DA micelle solutions were gently shaken at 37°C for 1 
week, the loading capacity and encapsulation efficiency were reduced to 0.012 and 12.0%, 
respectively. Additional studies to determine if the drug is released in a controlled fashion or if 
the CyA is thermally degraded are currently under way. In correlation with the results obtained 
via HPLC, PSA-DA prepared with DS values of 15-25 and 30-40% yielded small micelles with 
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broad size distributions, whereas PSA-DA prepared with DS values of 50-60 and 90-100% gave 
rise to larger micelles with narrow size distributions (Table 2). PSA-DA therefore forms micelles 
of higher stability that are more suitable for encapsulation of hydrophobic drugs at higher 
degrees of substitution. Both with and without CyA, the micelles increased in size with higher 
degrees of substitution. The result is in contrast with a number of literature reports that suggest 
polysaccharide-based micelle size should decrease with increased hydrophobic DS [224-227]. 
On the basis of studies on the evolution of micelle size with diblock copolymers [228], the 
increase in size is likely a result of an increased aggregation number as the merger of smaller, 
less stable micelles is facilitated by the increased number of hydrophobic alkyl chains. Evidence 
of micellar aggregation is further provided by a reduction in the size of CyA-loaded PSA-DA 
micelles, with a corresponding increase in size distribution, with 10 and 100 fold dilutions 
(Figure 4). According to previous studies, the reduction in size, and consequently aggregation 
number, are necessary upon micelle dilution to prevent instabilities in the system [228], The 
choice in using drug-loaded micelles to study dilution was made on the basis of the assumption 
that the drug-loaded micelles will be diluted upon clinical administration. As anticipated based 
on other micelle systems [224, 227, 229], drug encapsulation increased micelle size when PSA-
DA of the same DS with and without CyA were compared, although this difference was only 
statistically significant for a DS values of 15-25 and 50-60%. An increase in the amount of CyA 
initially added to the PSA-DA solution (DS 50-60%) from 10 to 30 wt % during micelle 
preparation yielded significantly larger micelles (180.6 ± 12.2). 
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Figure 4. The effect of dilution on the size (A) and polydispersity (B) of CyA loaded PSA-DA 
micelles with a DS of 50-60%. Asterisks indicate a significant different (p < 0.05) relative to 
PSA-DA micelles at a concentration of 10 mg/ml as determined using ANOVA followed by post 
hoc Fisher’s LSD. 
To better assess the stability of the micelles in a physiological setting, the impacts of 
temperature change upon the micelle size were probed using PSA-DA micelles with a DS of 50-
60%. A rise in temperature from 25 to 37 °C did not significantly affect the micelle size. 
Regardless of dilution or DS, the particle sizes obtained for the stable PSA-DA micelles are large 
enough to permit passive targeting. In cancer and inflammatory diseases, particularly rheumatoid 
arthritis, therapeutic carriers with large hydrodynamic radii to prevent renal filtration and 
increase circulation time can passively accumulate in the diseased tissue as a result of leaky 
vasculature, an effect referred to as “enhanced permeation and retention” [230-232]. AFM was 
used to confirm that the PSA-DA micelles, with and without CyA, possessed a spherical 
morphology (Figure 5). 
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Figure 5. AFM height images of unloaded (A) and CyA loaded (B) PSA-DA micelles.  The 
samples were diluted such that only one spherical micelle, as illustrated by the white spots, could 
be observed in each image. The image scale is in microns. 
Micelles were further characterized by zeta potential. Although there was significant day-
to-day variability, likely resultant from slight changes in the ionic strength of the water, for all 
DS values, the zeta potential varied between -30 and -40 mV. The zeta potential provides a 
gauge of the surface charge resultant from interaction with counter ions in a specified medium. 
Previous research has demonstrated that zeta potentials with absolute values >30 mV will permit 
electrostatic stabilization [233].  Therefore, the values obtained are indicative of micelle stability. 
For long-term storage, CyA-loaded PSA-DA micelle solutions with a DS of 50-60% were 
slowly frozen in a -80 °C freezer and lyophilized. Often, without the use of a cryoprotectant, 
aggregates will be observed following slow freezing and freeze-drying as a result of phase 
separation with an increase in concentration in one phase [234, 235]. Likewise, larger micelles 
can be formed following reconstitution if the micelles are broken as a result of physical stress 
during the freezing process [236]. Neither of these phenomena was observed for the PSA-DA 
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micelles, and dynamic light scattering yielded a size nearly identical to that obtained prior to 
lyophilization (106.6 ± 4.2). AFM further confirmed that the micelles were maintained through 
the freeze-drying process (Figure 6).  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure 6. AFM height imaged of CyA loaded micelles following lyophilization. The samples 
were reconstituted at high concentration and immediately prepared for imaging. The image scale 
is in microns. 
To the authors’ knowledge, only poly(lactic-co-glycolicacid)-poly(carboxybetaine) 
(PLGA-PCB)-based micelles have been reported to maintain their properties through the freeze-
drying process without the addition of a cryoprotectant. Similar to the PLGA-PCB system, the 
observed behavior likely results from strong hydration of the PSA, in combination with the 
formation of a protective shell of hydrophilic PSA around the distinctly hydrophobic DA core 
[237]. Of note, PEG-based micelle systems typically require the use of a cryoprotectant because 
PEG will crystallize and aggregate upon freeze-drying [238-241]. 
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3.3.5 Cytotoxicity of PSA-DA Micelle 
Cytotoxicity of PSA-DA was assessed using MH7A rheumatoid arthritis synovial 
fibroblasts using the WST-8 assay. The cell line was chosen based on future intended 
applications of the CyA-loaded PSA-DA micelles in targeted drug delivery for the treatment of 
rheumatoid arthritis. As shown in Figure 7, the IC50 was strongly dependent upon the DS, 
suggesting a role for DA in cytotoxicity. Presumably, the N-alkyl group interacts with the 
membrane and induces cell fragmentation, as has previously been reported for N-alkylated imino 
sugars [242]. PSA reacted only with EDC and NHS was shown to be nontoxic toward the cells, 
verifying that the side product did not contribute to cytotoxicity. As expected, CyA alone was 
also nontoxic toward the cells and encapsulation did not affect the IC50 of PSA-DA with a DS of 
50-60%. As suggested by studies on N-aklyated imino sugars, a small change in the length of the 
alkyl chain may have a large impact on cytotoxicity, with minimal influence on the CMC [242], 
and this will be a topic of further investigations. 
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Figure 7. WST-8 assay of MH7A synovial fibroblasts following incubation with PSA-DA of 
varying DS values for 24 hours at 37°C at concentrations from 0.015 – 0.5 mg/ml. The data was 
fit with a five parameter logistic, and the IC50 curves showed a shift to the left, as indicated by 
the arrow, with increasing DS (A). Therefore, as DS increased, the calculated IC50 decreased (B).   
3.4 Conclusion   
PSA is a relatively unexplored material for the prevention of premature clearance. In this 
study, preliminary investigations were conducted to demonstrate that PSA could be readily 
modified with a long-chain alkylamine to develop a material that naturally self-assembles in 
aqueous solution to form spherical micelles that can be used to encapsulate hydrophobic 
molecules, particularly cyclosporine A (CyA). Sizes and zeta potentials of the loaded and 
unloaded micelles indicate that the drug carriers possess acceptable properties for passive 
targeting of diseased regions; however, control of cytotoxicity warrants additional study. Future 
investigations will be aimed at assessing whether the PSA does prevent binding of serum 
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proteins and macrophage uptake, as claimed by previous researchers, and on in vitro and in vivo 
efficacy. 
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Chapter 4 Development, characterization, and in vitro 
efficacy of polysialic acid-polycaprolactone micelles 
Polysialic acid (PSA) has been identified as a natural, hydrophilic polymer that can be 
used to extend circulation time and improve therapeutic efficacy when used as the basis of drug 
carrier systems. Here, to further investigate the potential of PSA to alter the pharmacokinetic and 
pharmacodynamics profiles of associated therapeutics, PSA-based micelles were formed via self- 
assembly of PSA grafted with polycaprolactone (PCL) at a critical micelle concentration of 84.7 
± 13.2 µg/ml. Cyclosporine A (CyA), a therapeutic used in the treatment of rheumatoid arthritis, 
was loaded into the PSA-PCL micelles with a loading capacity and loading efficiency of 0.09 ± 
0.02 mg CyA/mg PSA- PCL and 29.3 ± 6.4 %, respectively. CyA loading resulted in a size 
increase from 66.8 ± 6.2 nm to 107.5 ± 9.3 nm, a favorable size range for drug delivery to 
inflamed tissue characterized by leaky vasculature, as occurs during rheumatoid arthritis 
pathogenesis. As an indicator of the stealth nature the micelles are expected to exhibit in vivo, 
the fixed aqueous layer thickness of the PSA-PCL micelles was determined to be 0.63 ± 0.02 
nm, comparable to that obtained for traditionally utilized poly(ethylene glycol) coated liposomes. 
The PSA-PCL micelles had a negligible effect on the viability of the SW982 synovial fibroblast 
cell line. Fluorescent microscopy was utilized to demonstrate uptake by the synovial fibroblasts 
through a non-receptor mediated form of endocytosis and intracellular separation of CyA from 
the micelle. 
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4.1 Introduction 
Due to the high cost and lengthy implementation timeline involved with drug discovery, 
drug delivery may serve as an alternative method to advance pharmaceutical sciences and human 
health. In addition, a numbers of therapeutics are characterized poor bioavailability, unfavorable 
biodistribution, and high cytotoxicity, particularly when administered systemically. Drug carrier 
systems are needed to improve drug efficacy and reduce cytotoxicity in the human body. To 
date, many studies have been conducted based on the theory proposed by Paul Ehrlich [243] to 
develop therapeutics which can be site-specifically delivered to the target tissue, with reduced 
accumulation in the healthy tissue. Most of these delivery systems are designed with the 
advantages of increased solubility, prolonged circulation stability, and high tissue specificity 
[13]. 
Among various nanoparticle systems, polymeric micelles have drawn much attention for 
the encapsulation of hydrophobic drugs since first reported in 1984 [12]. These micelles are 
formed from macromolecules composed of hydrophobic and hydrophilic segments. In an 
aqueous environment, the amphiphilic polymers self-assemble into a core-shell structure due to 
the aggregation of the hydrophobic moieties. Thus, hydrophobic drugs can be physically 
encapsulated into the core via hydrophobic interactions. In general, micelles provide therapeutics 
with improved solubility, enhanced stability, and an extended circulation time [14].  
When administered systemically, the majority of drugs are eliminated rapidly by the 
reticuloendothelial system (RES). Short drug circulation times have been a major challenge and 
have been liked to poor drug efficacy. Increased surface hydrophilicity can reduce the 
recognition and binding of plasma proteins to drug carriers and, thus, decrease the elimination of 
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drugs and prolong the circulation time. Consequently, the likelihood that the drugs will reach the 
target disease tissues is improved. To date, poly(ethylene glycol) (PEG)-based modification ha 
been the most common method to improve hydrophilicity and provide the drugs with so-called 
“stealth” properties to evade detection by the RES [244-246]. However, PEG may not be the 
ideal solution due to a non-biodegradable backbone, evidence of continuous accumulation inside 
the body, and problems with immunogenicity [48, 157, 158]. Moreover, the PEG coating is 
known to interfere with some of the steps involved in drug delivery. After localization to the 
diseased tissue, PEG coatings have been reported to hinder drug release from the carrier systems 
and reduce requisite drug-cell interactions [159-161].  
As an alternative, polysialic acid (PSA) is a relatively unexplored natural, non-toxic, and 
biodegradable polysaccharide that has the potential to prolong the circulation time of associated 
rugs and provide additional benefits. PSA is a linear homopolymer of α-2, 8-linked 5-N- 
glycolyneuraminic acid (Neu5Ac) and is widely produced by pathogenic bacteria, as well as the 
cells of vertebrates and higher invertebrates. Thus, PSA is highly involved and has multifarious 
roles in a wide variety of biological, immunological, and pathological processes [44-47]. Some 
pathogenic bacteria can escape the host immune system and evade the host tissues by producing 
a thick PSA coating on the cell wall [48]. In mammals, the major function of PSA is believed to 
be anti-adhesive properties that can change the cell-cell and cell-extracellular matrix interaction 
and promote neutral plasticity. PSA acts as a post-translational modification of neural cell 
adhesion molecules (NCAM), and the fifth Ig domain of NCAM is able to carry PSA at a high 
loading capacity. The significant negative charge and large hydrated volume of PSA can reduce 
NCAM-mediated adhesion and enable neuron cell migration. Typically, PSA expression is 
down-regulated in most tissues of the adults. However, during the neural injuries [49, 50] and 
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tumorigenesis [247, 248], PSA is expressed on the cell surfaces, which serves to alter cellular to 
abrogate cell adhesion and facilitate cell migration. The anti-adhesive properties are further 
supported by immune studies that demonstrate that the removal of PSA generates an “eat me” 
signal to macrophages to recognize and clear the uncoated bacteria, excess proteins, or dead cells 
[249]. 
Due to the natural anti-adhesive properties highlighted above, PSA has drawn attention in 
the field of drug delivery. Based on a series of studies on sialyated or polysialyated proteins, 
Gregoriadis et al. proposed that PSA was a potential material to increase the stability and 
circulation time of therapeutics inside the bodies [1]. PSA-drug conjugation has been used to 
increase the half-life of insulin [6], asparaginase [4, 5], and catalase [2, 3]. As a result, 
immunogenicity and antigenicity were reduced, and the efficacy of the proteins was improved. 
To date, several PSA-protein conjugates and Neu5Ac derivatives have been developed as 
vaccines and therapeutic agents [250, 251]. 
Compared to other drug delivery systems, nanoparticle-based targeted drug delivery 
systems have been shown to accumulate passively within tumor tissue and inflamed tissue due to 
the enhanced permeability of the leaky vasculature [252]. Previously, our lab developed micelles 
from PSA modified with a long chain hydrocarbon, decylamine [253]. Despite possessing the 
necessary physical properties in regards to size and surface charge, the micelles were cytotoxic 
towards a synovial fibroblast cell line. Here in, we develop and characterize non-cytotoxic, PSA- 
based micelles via grafting of the PSA with amine-terminated polycaprolactone (PCL), a 
hydrophobic, non-toxic polymer that can be degraded in the human body by ester hydrolysis 
(Figure 8) [254]. The protective role the PSA is thought to play in vivo was preliminarily 
evaluated by measurement of the fixed aqueous layer thickness (FALT). FALT has previously 
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been correlated with the ability of carrier systems to prevent opsonization and, consequently, 
uptake by the RES [205, 255-258]. Cyclosporine A (CyA), a therapeutic used in the treatment of 
rheumatoid arthritis was used as a model compound to demonstrate the capacity of the micelles 
to encapsulate hydrophobic molecules. Fluorescence microscopy experiments were used to 
demonstrate cellular uptake of the drug-loaded micelles and release of the CyA from the 
micelles. 
4.2 Materials and Method 
4.2.1 Material 
Colominic acid sodium salt (PSA, isolated from E. coli, Mw 30 kDa) was obtained from 
Nacalai USA (San Diego, CA). N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC), N,N’-
dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS), ethylenediamine, m-
chloroperoxybenzonic acid, benzyl alcohol, 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD), ɛ-
caprolactone (ɛ-CL), and Boc-gly-OH were purchased from Sigma-Aldrich (St. Louis, MO) and 
used as received. Trifluoroacetic acid (TFA) (peptide synthesis grade), HPLC grade acetonitrile, 
dichloromethane, and anhydrous DMSO were also obtained from Sigma-Aldrich. (St. Louis, 
MO). Dichloromethane was distilled before use. Dowex 50WX 2 ion-exchange resin and pyrene 
were purchased from Acros organics (Pittsburgh, PA) and tetrabutylammonium bromide was 
obtained from Fluka (St. Louis, MO). The SW982 synovial fibroblast cell line was acquired from 
ATCC (Manassas, VA). Fetal bovine serum (FBS) was obtained from Lonza (Allendale, NJ) and 
cyclosporine A (CyA) was puchased from Enzo Life Sciences (Farmingdale, NY.). Dulbecco’s 
Modification of Eagle’s Medium (DMEM) supplemented with 4.5 g/L glucose, L-glutamine & 
  
58 
sodium pyruvate was procured from Mediatech, Inc. (Manassas, VA). Purified soluble collagen 
was purchased from Devro Pty Ltd. (Bathurst, NSW, Australia). Alexa Fluor® 488 succinimdyl 
ester and sulforhodamine 101 cadaverine were acquired from Invitrogen (Grand Island, NY) and 
AnaSpec (Fremont, CA), respectively. 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 
cholesterol and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-2000] (DSPE PEG 2000) were obtained from Avanti Polar Lipids (Alabaster, AL) and 
used without further purification. (Dimethylamino)pyridine-p-toluensulfonic acid (DPTS) was 
formed from hydrated p-toluenesulfonic acid and 4-(dimethylamino)pyridinium following a 
known protocol [259]. 
4.2.2. Preparation of polysialic acid-polycaprolactone (PSA-PCL) micelles 
4.2.2.1. Synthesis of polycaprolactone (PCL) 
PCL-OH was synthesized according to a published procedure [260]. To a previously 
incubated solution of benzyl alcohol (5.5 µL, 5.31×10-2 mmol) and TBD (0.04 M in toluene, 3.7 
mL, 0.148 mmol), ɛ-CL (0.82 mL, 7.4 mmol) was added and the mixture was stirred at room 
temperature, under nitrogen, for 2.5 hr. The polymerization was then quenched by precipitation 
into cold methanol and PCL-OH was isolated as colorless oil. Residual catalyst and unreacted 
monomer were removed from the isolated polymer by repeated precipitation into cold methanol. 
Polymer formation was confirmed by 1H NMR and gel permeation chromatography in 
chloroform with polystyrene standards was used to estimate molecular weight (Mw =8216 
g/mol). 
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4.2.2.2. Synthesis of Amine-Terminated PCL (PCL-gly-NH2) 
A two-step process was used to generate PCL-gly-NH2 [261]. 200 mg of 
hydroxylterminated PCL (0.026 mmol), 5.5 mg DCC (0.026 mmol), and 14.6 mg DPTS (0.026 
mmol) were dissolved in 6 ml anhydrous dichloromethane under nitrogen, and 4.6 mg BOC-
glycine (0.026 mmol) were added. The reaction solution was stirred for 48 h at room 
temperature. After filtration, the solution was added drop-wise into 30 ml of cold methanol. The 
white precipitate was collected and dried under vacuum oven overnight. The resultant 141.1 mg 
of PCL-gly-Boc (Mw =8374 g/mol, ~ 0.017 mmol) was dissolved in 7 ml anhydrous 
dichloromethane and 7 ml of TFA was added via syringe. The mixture was stirred at room 
temperature for 2 h under nitrogen. The product was obtained by rotary evaporation followed by 
drying at 70°C in a vacuum oven. Formation of PCL-gly-Boc and deprotection to yield PCL-gly-
NH2 were confirmed by 1H NMR (300 MHz, CD3Cl). 
4.2.2.3. Synthesis of PSA-PCL 
To improve the solubility of PSA in DMSO, the sodium ion was exchanged for 
tetrabutylammonium using a procedure adapted from the literature [262]. 600 mg Dowex 50 
WXZ and 750 mg tetrabutylammonium bromide (2.26 mmol) were mixed in 15ml of DI water, 
and the mixture was stirred gently for 1 hour. The Dowex 50 WXZ was washed several times 
with DI water to remove unbound tetrabutylammonium bromide. The washed Dowex was 
transferred into 10 ml of 2% aqueous (w/w) PSA (200 mg, 0.65 mmol sialic acid monomer), and 
the solution stirred for 2 hours at room temperature. The resin was separated from the liquid by 
centrifugation at 1000 rpm for 5 min. Ion exchanged PSA was isolated via lyophilization.  
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To conjugate PCL-gly-NH2 to PSA, 100 mg of ion exchanged PSA (0.32 mmol sialic 
acid monomer), 10.1 mg DCC (0.048 mmol, 0.15 equiv relative to sialic acid monomer), and 
26.8 mg DPTS (0.048 mmol, 0.15 equiv) were combined in 6 ml of anhydrous DMSO, and the 
solution was stirred for 1 h at room temperature under nitrogen. Simultaneously, 133 mg PCL-
gly-NH2 (0.016 mmol, 0.05 equiv) were dissolved in 6 ml anhydrous dichloromethane in a 
separate round bottom flask. After 1h, the dichloromethane solution was transferred to the 
DMSO solution via cannula. The mixture was allowed to stir overnight at room temperature. 
After filtration, the solution was dialyzed against 150mM NaCl solution overnight to remove 
solvent and exchange tetrabutylammonium for sodium. Residual dichloromethane was removed 
by rotary evaporation, and the product was isolated by lyophilization. The product was washed 
with DI water and lyophilized again to ensure removal of unreacted PCL-gly-NH2. The 
formation of PSA-PCL was confirmed by 1H NMR. The degree of substitution (DS) of PCL to 
sialic acid monomer found by 
DS= (!!)(!!.!"!!.! )( !!!"#!!ɛ!!")      (4.1) 
where A1.35 and A2.1 are the peak areas at δ 1.35 and 2.1 ppm, respectively. 
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Figure 8. Synthesis of polysialic acid-polycaprolactone (PSA-PCL) for micelle formation. 
4.2.3 Characterization of PSA-PCL micelles 
4.2.3.1. Critical micelle concentration (CMC) 
CMC was evaluated via steady-state fluorescence using pyrene as a probe [206, 263]. 8.1 
µL of a 1.24 × 10-4 M pyrene stock solution in acetone was added to nine individual vials, and 
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the acetone was allowed to evaporate by placing on a 65°C hot plate for 15 min. Simultaneously, 
a dilution series of aqueous PSA-PCL solutions with concentrations ranging from 1 mg/ml to 3.9 
µg/ml was prepared. 1 ml of the aqueous micelle solutions was added to the nine vials with 
pyrene. The solutions were sonicated for 30 min at room temperature and heated with shaking at 
65 °C for 4 h to achieve equilibration. After cooling in the dark overnight, excitation spectra 
were recorded at an emission wavelength of 390 nm with a QuantaMaster-4/2005 sensitivity 
enhanced (QM-4/2005 SE, Photon Technology International) fluorescence spectrophotometer. 
4.2.3.2. Size and zeta potential 
Size, polydispersity, and zeta potential of PSA-PCL micelles, with and without 
encapsulated CyA, were obtained with a Zetasizer Nano ZS (Malvern Instruments). Aqueous 
samples were prepared by dissolving 2 mg PSA-PCL in 1 ml DI water. For dynamic light 
scattering, the temperature for measurement was 25°C, and the angle of scattered light was 173°. 
Micelle sizes are reported as the mean of the sizes derived from the number distributions 
plus/minus the standard deviation, while size distributions are reported as the mean of the 
polydispersity indices plus/minus the standard deviation. 
4.2.3.3. Transmission electron microscopy (TEM) 
Lyophilized PSA-PCL was dissolved in DI water at a concentration of 0.1 mg/ml to 
facilitate self-assembly of micelles. 20 µl of the PSA-PCL micelle solution was pipetted onto a 
formvar/carbon coated copper grid (Electron Microscopy Sciences, Inc.). The excess micelle 
solution was removed, and the sample was stained with methylamine vanadate prior to imaging 
with a JEOL 2000EX TEM at 100 kV at the N.C. Brown Center for Ultrastructure Studies at the 
SUNY College of Environmental Science and Forestry. 
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4.2.3.4. Cytotoxicity 
Cytotoxicity of PSA-PCL was evaluated via WST-8 assay (Cayman Chemical Company, 
Ann Arbor, MI) using the SW892 synovial fibroblast cell line. Cells were seeded into a 96-well 
plate at a density of 10,000 per well and cultured for 24 h with DMEM plus 10% FBS at 37°C, 
5% CO2. Following sterile filtration, PSA-PCL micelles were added at concentrations ranging 
from 0.156-20 mg/ml. After incubating for 24 h, the media was removed and 10 µl of WST-8 
reagent and 100 µl of fresh media were added to each well. After a 90 min incubation period, the 
absorbance was measured at 450 nm by a Synergy 2 multimode microplate reader (Biotek 
Instruments). SW982 cells cultured without PSA-PCL were used as controls. The experiment 
was repeated independently three times. IC50 concentrations were determined from a four 
parameter logistic generated using Kaleidagraph software. 
4.2.4. Encapsulation of cyclosporine A (CyA) 
CyA was encapsulated using a previously established approach [264]. 3 mg of CyA was 
dissolved in 4 ml of a 1:1 mixture of methanol and DMSO. 10 mg of PSA-PCL were added. To 
initiate micelle formation, 1 ml of DI water was added. The solution was transferred to a dialysis 
membrane (6-8 kDa) and dialyzed against DI water for 2 days to remove organic solvent and 
facilitate self-assembly with entrapped CyA. Drug-loaded micelle was isolated by lyophilization. 
Dynamic light scattering measurements confirmed that the micelles were stable to the freeze-
drying procedure without the addition of a cryoprotectant. 
 Loading capacity (LC) and loading efficiency (LE) of the CyA-loaded PSA-PCL 
micelles were assessed with a Prominence Ultrafast Liquid Chromatography System (UFLC, 
Shimadzu Scientific Instruments, Japan) equipped with an SPD-20AV UV detector, a SIL-20A 
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autosampler, a DGU-20A3 degasser, and a Shim-pack XRODS/ C8/Phenyl column (3mm i.d. 
×50mm). 10 mg of lyophilized, CyA-loaded PSA-PCL was dissolved in 4 ml of mobile phase, a 
65:35 mixture (v/v) of pure HPLC grade acetonitrile and DI water, and mixed well. All samples 
were filtered through 0.25 µm filter prior to injection. An injection volume of 100 µL was used, 
and the flow rate and detection wavelength were set to 210 nm and 0.5 ml/min, respectively. At a 
column temperature of 40°C, CyA was observed as a broad peak centered at an elution time of 
8.3 min. A calibration curve was constructed by determining the area under the peak using 
PeakFit 4.2 software for eight CyA solutions with known concentrations ranging from 50 to 400 
µg/ml. Samples of CyA-loaded micelles were diluted with acetonitrile to release encapsulated 
drug (65 acetonitrile: 35 water). LC and LE were determined as: 
LC= 
!!"#!!"#$%$!!"#!!"#      (4.2) 
LE= 
!!"#!!"#$%$!!"#!!""#"       (4.3) 
where WCyA-loaded is the amount of CyA incorporated into the micelles, as determined using the 
calibration curve, and WPSA-PCL and WCyA-added are the amounts of PSA-PCL and CyA used, 
respectively . 
4.2.5 Comparison of PSA-PCL micelles to PEG-coated liposomes 
4.2.5.1. Preparation of PEG-coated liposomes 
Small unilamellar vesicles of average diameter of 100 nm composed of 62 mol% DPPC, 
33 mol% cholesterol and 5 mol% DSPE-PEG 2000 were prepared by the vesicle extrusion 
methods. In brief, the lipids were suspended in chloroform and mixed in a round bottom glass 
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vial. The solvent was evaporated, and the dried lipid film was resuspended with double deionized 
water and hydrated overnight at 4 °C. The total lipid concentration was 2 mg/ml. The liposomes 
were homogenized by passing them with 1800 kPa 11 times through polycarbonate filters of 100 
nm pore diameter (Whatman Inc., Clifton, NJ) using a high-pressure extruder (Northern Lipids 
Inc., Vancouver, Canada). 
4.2.5.2. Determination of the fixed aqueous layer thickness (FALT) 
The FALTs of PSA-PCL micelles and PEG-coated liposomes were determined following 
a previously described method based on the Gouy-Chapman theory. Zeta potentials for micelles 
and PEG-coated liposomes were obtained in the following concentrations of aqueous NaCl: 10, 
50, 100, 150, and 200 mM. Using eq. 4, FALT was estimated from a plot of zeta potential ψ) 
versus the Debye-Huckel parameter (κ = √(C/0.3), where C is the molality of NaCl). 
4.2.6 Cellular uptake of CyA-loaded PSA-PCL micelles 
4.2.6.1. Synthesis of cyclosporine amine (CyA-NH2) 
To facilitate attachment of a fluorescent tag, a CyA analog with a reactive functional 
group was prepared. The procedure outlined herein for the preparation of CyA-NH2 was adapted 
from a previous study on the synthesis of cyclosporine A derivatives [265] (Figure 9). Briefly, 
200 mg CyA (166 µmol), 32 mg m-chloro-peroxybenzonic acid (186 µmol), and 40 mg 
anhydrous sodium carbonate (380 µmol) were combined in 20 ml of anhydrous methylene 
chloride, and the reaction solution was stirred overnight under N2 at room temperature. The 
solution was washed with 20% sodium bisulfite and 10% sodium carbonate. The organic layer 
was dried over anhydrous magnesium sulfate, filtered, and concentrated to yield 190 mg of 
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crystalline product. This was immediately dissolved in 20 ml of anhydrous THF and refluxed 
under N2 with excess ethylenediamine (400 µl, 359.6 mg, 5.98 mmol) for 24 h at 80°C. The 
solution was concentrated, and flash chromatography on silica gel (SiliaFlash® F60) was used to 
isolate the product. The colorless byproduct was eluted first with hexane/acetone (1:2), and then 
methanol/dichloromethane (4:1) was used to obtain the product as a yellow residue. Product 
formation was confirmed by high resolution electrospray ionization mass spectrometry on a 
Bruker 12 Tesla APEX –Qe FTICR-MS with an Apollo II ion source at the COSMIC laboratory 
of Old Dominion University. HRMS calculated for CyA-NH2 [M+Na]+ 1300.8942; Found 
1300.8904 (Figure 34). 
	  
Figure 9. Synthesis of amine-terminated CyA 
4.2.6.2. Preparation of fluorescently tagged CyA and PSA-PCL 
Fluorescently labeled PSA-PCL was prepared by dissolving 40 mg of PSA-PCL in 4 ml 
of DI water, followed by the addition of 15.5 mg EDCI (99.9 µmol), 11.5 mg NHS (99.9 µmol) 
and 400 µl sulforhodamine 101 cadaverine (1 mg, 1.45 µmol). The pH was adjusted to 4.75, and 
the solution was stirred overnight with protection from light at room temperature. Fluorescently 
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labeled PSA-PCL was isolated by lyophilization. Fluorescently labeled CyA was encapsulated 
within fluorescently labeled PSA-PCL as described above for unlabeled material.  
Fluorescently labeled CyA was synthesized by dissolving 12 mg of CyA-NH2 in 1 ml 
DMSO, followed by the addition of 250 µl (0.25 mg, 0.39 µmol) Alexa Fluor® 488 carboxylic 
acid, succinimidyl ester, mixed isomers in DMSO. The solution was stirred for 2 h with 
protection from light at room temperature and then dialyzed overnight to remove unreacted 
fluorescence tag. Fluorescently labeled CyA was isolated by lyophilization.  
4.2.6.3. Microscopy 
35 mm Glass-bottom dishes (MatTek, Ashland, MA) were coated with collagen prior to 
use to improve cell viability and morphology. Collagen was dissolved in 0.02 M acetic acid at a 
concentration of 50 µg/ml, and 1 ml of the resultant solution was sterile filtered and added to 
each microscopy plate. After 1 h at room temperature, excess collagen solution was removed by 
gentle aspiration, and the plates were rinsed 3 times with 1xPBS. The plates were air dried 
overnight inside a biosafety cabinet. SW982 cells were seeded into the collagen-coated plates at 
a density 1 million cells/plate. After 24 h of incubation at 37°C, the media was removed and 
sterile filtered fluorescently labeled CyA-loaded PSA-PSA micelle solution was added, The 
plates were washed 3 times with 1xPBS before imaging, and images were obtained with a Nikon 
Eclipse Ti inverted microscope at 15 and 60 min post-administration. Experiments were 
conducted at both room temperature and 4 degrees in order to garner a better understanding of 
the uptake mechanism. 
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Figure 10. To observe cellular uptake and intracellular separation of PSA-PCL and CyA, (A) 
PSA-PCL was conjugated to sulforhodamine 101 cadaverine, while (B) CyA modified to include 
a free amine moiety was linked to Alexa Fluor® 488. 
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4.3 Results and discussion 
4.3.1. Synthesis and characterization of PSA-PCL micelles 
PSA-PCL was successfully synthesized via amide bond formation between PSA and 
amine-terminated PCL (Figure 8). Low molecular weight PCL (Mw ~ 8000) was synthesized via 
dual activation of the benzyl alcohol initiator and ɛ-caprolactone monomer with 1, 5, 7-
triazabicyclo[4.4.0]dec-5-ene (TBD) catalyst [260] (Figure 35). The terminal hydroxyl group of 
the PCL polymer was subsequently conjugated to Boc-protected glycine (Figure 36). Acid-
catalyzed deprotection yielded the desired amine-terminated PCL [261] (Figure 37). To facilitate 
the reaction between organic soluble PCL and water soluble PSA, the counterion of PSA was 
exchanged from sodium to tetrabutylammonium [262]. Following PSA-PCL conjugation in a 
mixture of methylene chloride and DMSO, the ion was changed back to sodium by dialyzing the 
product against 150 mM aqueous NaCl for 2 days. The latter step was necessary to prevent 
potential toxicity from the tetrabutylammonium salt. From 1H NMR, the degree of substitution, 
defined as the percentage of monomers on the PSA backbone grafted with PCL, was determined 
to be approximately 1%, or a weight ratio of 4 PSA: 1 PCL (Figure 38). 
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Figure 11. A representative plot showing the change in I339/I337 for pyrene as the concentration 
of PSA-PCL (mg/mL) is increased. 
The capacity for PSA-PCL to self-assemble into micelles was assessed using pyrene as a 
fluorescent probe based upon established methodology [206, 263]. As the PSA-PCL 
concentration was increased past that required for micelle formation, i.e. the critical micelle 
concentration (CMC), the pyrene achieved a new equilibrium between the hydrophobic core of 
the micelle and the hydrophilic aqueous solution. These changes in the distribution between the 
hydrophilic and the hydrophobic phases resulted in a measureable shift in the pyrene excitation 
spectrum. By plotting the ratio of intensities at 339 and 337 nm (emission wavelength = 390 
nm), as a function of the log of PSA-PCL concentration, the CMC was determined to be 84.7 ± 
13.2 µg/ml from the intersection of the tangent of the inflection point with the horizontal tangent 
of the low concentration points (Figure 11). The low value obtained for PSA-PCL is consistent 
with the CMC of decylamine-modified PSA [253] and other polysaccharides based micelle 
systems [206, 263, 266]  
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The size of the PSA-PCL micelles without encapsulated therapeutics was 66.8 ± 6.2 nm, 
as determined by dynamic light scattering and confirmed by transmission electron microscopy 
(Figure 12 and figure 13).  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure 12. Dynamic light scattering was used to determine the size and polydispersity of PSA-
PCL micelles without (solid line) and with (dashed line) encapsulated Cyclosporine A. Drug 
loading resulted in a significant size increase; however, both sizes were within the preferred size 
range for drug delivery. 
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Figure 13. Transmission electron microscopy was used to confirm spherical micelles with a size 
of approximately 70 nm were obtained via self-assembly of PSA-PCL. 
Based on size alone, PSA-PCL micelles are suitable for use as part of a treatment 
strategy. In drug delivery, particle size has a known significant impact on drug distribution, 
excretion, and efficacy [267]. Microparticles primarily accumulate in the lungs, while 
nanoparticles with a size range larger than 200 nm are usually trapped and eliminated quickly by 
reticuloendothelial system (RES). In contrast, if the size is under 10 nm, the particles are often 
rapidly excreted by the kidneys. Therefore, the particles intended for long circulation should 
ideally possess a size between 10 and 200 nm, as was obtained here [256]. Moreover, inflamed 
tissue, such as that found in rheumatoid arthritis, has poorly organized vascular structure due to 
angiogenesis, immune cell accumulation, and an imbalance in the secretion of signaling 
molecules [268, 269]. Nanoparticles with sufficient size to evade kidney filtration, but small 
enough to avoid RES uptake, will passively accumulate within inflamed tissues [182].  
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To provide an initial assessment of the surface properties, the zeta potential of the PSA-
PCL micelles was determined to be -29.7 ± 8.0 mV. As empirically established, an absolute 
value between 30-40 mV indicates a stable colloidal particle system with low affinity to blood 
proteins [270]. Thus, initial size and surface charge measurements suggest that PSA-PCL micelle 
may serve as effective carrier system. As discussed below, to obtain a better sense of surface 
properties, zeta potential measurements were also used in conjunction with Guoy-Chapman 
theory to assess the fixed aqueous layer thickness (FALT). 
Cytotoxicity was assessed using the SW982 human synovial sarcoma cell line via WST-8 
assay. The cell line was chosen based upon future in vitro tests that will be used to assess the 
efficacy of CyA-loaded PSA-PCL micelles in the treatment of rheumatoid arthritis. As 
represented in Figure 14, the IC50 for PSA-PCL was determined to be 10.5 ± 1.7 mg/ml, a value 
greater than or comparable to other polymeric micelle systems that are considered to be non-
cytotoxic [271, 272]. In addition, the IC50 value obtained here was significantly greater than that 
obtained previously for micelles prepared from polysialic acid modified with short chain 
hydrocarbons [253]. The lack of observed cytotoxicity provides an indicator of biocompatibility 
for subsequent in vivo experiments. Notably, CyA has previously been shown to be non-
cytotoxic towards human synovial fibroblasts [253]. 
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Figure 14. A representative plot illustrating the use of the WST-8 assay to assess cytotoxicity 
upon administration of a range of PSA-PCL concentrations (0.08 – 20 mg/ml) to the SW982 
synovial cell line for 24 h at 37°C. A four parameter logistic curve fit was used to determine an 
IC50 of 10.5 ± 1.7 mg/ml (N = 3). 
4.3.2 Encapsulation of cyclosporine A (CyA) 
CyA was chosen as a representative drug to evaluate the potential of PSA-PCL as a 
carrier system for use in the treatment of rheumatoid arthritis. CyA is a regularly used disease 
modifying anti-rheumatic drug with strong immunosuppressive properties. Despite a 
demonstrated ability to alter the progression of rheumatoid arthritis in many patients, CyA is 
nephrotoxic; therefore, frequent monitoring for signs of possible renal dysfunction and kidney 
damage is necessary [219, 273]. In part, the observed toxicity is likely a consequence of the 
large, between-patient variability in pharmacokinetic parameters [274]. Thus, CyA is an ideal 
candidate for incorporation into a drug delivery system that will serve to improve the 
pharmacokinetic profile. 
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The therapeutic efficacy of CyA is primarily attributed to inhibition of T cell activation 
[275, 276]; however, CyA has also been shown to reduce the expression/secretion of pro-
inflammatory cytokines, adhesion molecules, metalloproteinases, and angiogenic growth factors 
by several other cell types associated with rheumatoid arthritis, particularly synovial fibroblasts 
[277-279]. The mechanism by which CyA acts in rheumatoid arthritis and other pathologies has 
not been fully elucidated. Although numerous studies have demonstrated the interference of CyA 
with calcium-dependent signaling pathways [275, 276], initial activity has been postulated to be 
due to partitioning of the hydrophobic drug into the phospholipid membrane and subsequent 
alteration of phospholipid metabolism [280, 281]. As will be discussed further below, a 
fluorescently tagged CyA derivative was used in this study to allow for visualization of CyA 
partitioning to the membrane following administration of the drug-loaded micelles. 
An established dialysis method was used to facilitate loading of CyA into the PSA-PCL 
micelles [264]. A solution of CyA and PSA-PCL in a mixture of methanol, DMSO, and water 
was extensively dialyzed against water until drug-loaded micelles were formed and most of the 
residual organic solvent within the dialysis tubing was removed. After dialysis, non-encapsulated 
CyA was removed by centrifugation, and the drug-loaded micelles were isolated for storage as a 
white powder via lyophilization. Size measurements before and following re-dispersion in water 
verified that the CyA-loaded PSA-PCL micelles were stable to freeze drying without the addition 
of a cryoprotectant, as is typically required for PEG-modified systems [234, 282]. The size of the 
micelles increased to 107.5 ± 9.3 nm upon CyA loading; however, the polydispersity index was 
significantly lowered from 0.32 ± 0.05 to 0.16 ± 0.01, suggesting that the interaction of the PCL 
with the CyA enhances the stability of the micelles. 
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CyA encapsulation was quantified by high performance liquid chromatography. The 
loading capacity and loading efficiency were determined to be of 0.09 ± 0.02 mg CyA/mg PSA-
PCL and 29.3 ± 6.4 %, respectively. Of note, these values were significantly higher than those 
obtained for a previously developed polysialic-acid based micelle system that utilized short chain 
hydrocarbons to initiate self-assembly [253]. Presumably, the large, hydrophobic CyA molecules 
have more favorable interactions with the long hydrophobic chains of PCL relative to the short 
chain hydrocarbons. The latter result correlates with the observed reduction in the polydispersity 
index. Moreover, these values were comparable to those obtained by other researchers for drug 
loaded polymeric micelle systems [283, 284]. 
4.3.3. Comparison of PSA-PCL micelles to PEG-coated micelles 
PEG modification has long been used as a method to reduce undesirable interactions with 
the RES and extend the circulation time of drug delivery systems. One of the proposed 
mechanisms by which PEG modification gives this so-called stealth nature to drug delivery 
systems, particularly liposomes, is via an increased affinity to water molecule. Thus, several 
researchers have begun using the fixed aqueous layer thickness (FALT) as a quantitative 
measure of the ability of colloidal carriers to resist opsonization and subsequent uptake by the 
RES [205, 255-258]. 
To measure the FALT, the PSA-PCL micelles were suspended in aqueous solution with 
increasing NaCl concentrations, and the zeta potentials were measured. Assuming a spherical 
particle and a homogeneous charge distribution, Guoy Chapman theory can be applied to give 
the zeta potential ψ (L) as a function of the Debye Huckel parameter, κ = C1/2/0.3 [205, 257, 
258, 285]: 
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𝐿𝑛𝜓 𝐿 = 𝐿𝑛𝐴 – 𝜅𝐿     (4.4) 
where C is the molarity of the NaCl and A is a constant. Plotting Ln ψ (L) versus κ yields a 
straight line with a slope L, equal to the thickness of the FALT in nm. From eq. 4.4, the FALT 
for the PSA-based micelles was calculated to be 0.63 ± 0.03nm. For comparison, traditional, 
PEGcoated liposomes were also prepared, and the FALT was determined to be 0.77 ± 0.11nm. 
The comparable values (p > 0.05) obtained for the PSA-PCl micelles and PEG-coated liposomes 
suggest that PSA can provide a similar aqueous layer compared to that afforded by PEG. 
Furthermore, the FALT of the PSA-PCL micelles was greater than and near those reported in the 
literature for unmodified liposomes and liposomes coated with low molecular weight PEG, 
respectively [205, 255-258]. 
4.3.4. Cellular uptake and intracellular therapeutic release 
To facilitate visualization of micelle uptake and therapeutic release in vitro, the PSA-PCL 
micelles and CyA were labeled with red (sulforhodamine) and green (Alexa Fluor 488) 
fluorescent tags, respectively (Figure 15). Dynamic light scattering was used to verify that the 
size and zeta potential of the drug-loaded micelles were unaffected by the presence of the 
labeling moieties. 
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Figure 15. Color composite of fluorescence microscopy images demonstrating nanoparticle 
uptake and intracellular drug release at room temperature. Use of identical imaging settings 
permits direct comparison of fluorescence intensities. Left image: cells not incubated with 
nanoparticles result in negligible signal. Middle image: cells after 15 minutes incubation with the 
nanoparticles. Clearly visible is the separation of the PSA-PCL drug carrier (red) and CyA 
(green) that appear strongly localized at the plasma membrane. Right Image: Cells after 60 
minutes incubation. Fluorescence signals from PSA-PCL (red) and CyA (green) are much higher 
indicating much increased nanoparticle uptake. Scale bars are 5 µm. 
	  
Figure 16. Color composite of fluorescence images demonstrating nanoparticle uptake and drug 
release at 4°C. Acquisition parameters are the same as in Figure 15, but because of significantly 
lower intensities different brightness settings had to be chosen. For a direct comparison see 
Figure B1 and B2 in APPENIX B. Left image: cells not incubated with nanoparticles result in 
negligible signals. Middle image: cells after 15 minutes incubation with the nanoparticles. Some 
uptake and separation of the PSA-PCL drug carrier (red) and CyA (green) is apparent. Right 
Image: Cells after 60 minutes incubation. Fluorescence signals from both PSA-PCL (red) and 
CyA (green) have increased indicating additional drug-carrier uptake over time. Scale bars are 5 
µm. 
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As shown in Figure 15, the SW982 cells showed time-dependent uptake of the CyA-
loaded micelles, as well as rapid intracellular release of the drug from the carrier system. The 
observed migration of CyA from the intracellular space to the membrane lends support to the 
notion that the immunosuppressive activity of CyA is, in part, a result of phospholipid bilayer 
disruption. Purportedly, changes in membrane organization and fluidity following interactions 
with CyA yield a reduction in phosopholipid metabolism that inhibits cellular activation [280, 
281, 286-288]. An identical set of experiments was conducted at 4°C, rather than room 
temperature, to preliminarily assess the mechanism of cellular uptake (Figure 16). The 
significant reduction in fluorescence intensity suggests that internalization of the micelles is 
primarily through energy-dependent endocytic pathways [289-291]. Of note, rheumatoid arthritis 
synovial fibroblasts exhibit enhanced endocytic activity compared to healthy synovial fibroblasts 
[292]. This characteristic is expected to further enhance the targeting ability of carrier systems 
that enter cells via energy dependent pathways, including the PSA-PCL micelles. 
4.4 Conclusion 
In this study, PSA-PCL micelles were developed as carrier systems for CyA, a disease 
modifying anti-rheumatic drug that is associated with significant, adverse side effects. Physical 
characterization, including size and zeta potential, demonstrated that the micelles possess 
favorable properties for drug delivery. The PSA gave rise to an aqueous layer, similar to that 
found with PEGylated liposomes, that is expected to confer “stealth” like properties in vivo. In 
vitro studies verified that rheumatoid arthritis synovial fibroblasts are able to internalize the 
CyA-loaded micelles. Furthermore, CyA was released from the PSA-PCL micelle upon uptake 
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and, subsequently, partitioned into the phospholipid membrane, suggesting a mechanism of 
action that begins with membrane disruption. 
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Chapter 5 Development and characterization of 
polysialic acid-N, N, N-trimethyl chitosan 
nanoparticles 
In drug delivery, the nanoparticles must be of proper size and charge to achieve high 
efficacy and low toxicity of associated therapeutics. In this study, nanoparticles were developed 
via ionic gelation of two polysaccharide-based molecules, negatively charged polysialic acid 
(PSA) and positively charged N, N, N-trimethylchitosan (TMC). PSA is unique in that the highly 
hydrated backbone may be used in a manner similar to that of poly (ethylene glycol) to extend 
circulation times. Although not necessary for nanoparticle formation, sodium tripolyphosphate 
(TPP) was added to enhance stability, as indicated by a reduced polydispersity. We investigated 
three different ratios by weight of PSA: TMC (0.5:1, 1:1, 1:2 and five different TPP 
concentrations ranging from 0.1 mg/ml to 0.8 mg/ml. As controls, nanoparticles were also 
formed without PSA from chitosan and TMC with TPP. Optimal size and surface charge were 
achieved with a PSA: TMC weight ratio of 0.5:1 and a TPP concentration 0.2 mg/ml. For the 
nanoparticles prepared in the latter fashion, a more in depth characterization was conducted. The 
nanoparticles were distinct solid, spherical nanogels with a size of 106 ± 25 nm, an ideal size to 
reduce uptake by the reticuloendothelial system while facilitating passive targeting of diseased 
tissue. The zeta potential of the nanoparticles was +33.9 ± 1.2 mV, suggesting that the 
nanoparticles will be stable under physiological conditions. Encapsulation and controlled release 
by the nanoparticles was demonstrated using methotrexate, a therapeutic indicated in both cancer 
and rheumatoid arthritis. The results obtained thus far strongly indicate that PSA-TMC 
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nanoparticles are suitable drug carrier systems for systemic administration. 
5.1 Introduction 
One century ago, Paul Ehrlich proposed that drugs should be developed selectively to 
treat diseased cells without damaging healthy tissues [243]. Directed by this concept, many 
studies have been done to investigate various materials as potential drug delivery systems for a 
number of diseases with broad goals of facilitating controlled release, improving efficacy and 
reducing side effects. Among the different types of drug delivery systems, nanoparticles have 
drawn the most attention due to numerous benefits, such as reduced toxicity, as well as improved 
efficacy, bioavailability, and solubility [254, 293]. Furthermore, nanoparticles have been 
demonstrated to accumulate passively within tumor tissue due to the EPR (enhanced 
permeability and retention) effect [252]. 
For systemic drug delivery, one of the most sought after properties is a long circulation 
time that can increase the chance of drugs' accumulation in diseased tissues, which can thereby 
improve drug efficacy. Polyethylene glycol (PEG) conjugates, micelles, and nanoparticles are 
commonly used to shield drugs from rapid clearance. Despite demonstrated efficacy, particularly 
in the treatment of cancer, PEG-carrier systems have several draw- backs when considered for 
the treatment of chronic conditions, such as rheumatoid arthritis and other inflammatory 
diseases. Of note, higher molecular weight PEG chains, with a large associated hydrodynamic 
radius, cannot be renally excreted. Although this effect is desirable for EPR, no long term studies 
have been done to date to elucidate if the PEG is cleared once the payload of the carrier sys- tem 
is released and/or where the PEG accumulates and the impact of this accumulation [158, 294, 
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295]. Furthermore, upon intravenous administration, PEGylated therapeutics may elicit an 
adverse immunological response through complement activation [158, 295]. Although in the 
short term the benefits of PEG overshadow the potential drawbacks, an alternative to PEG 
should be sought for diseases that require extended medical care. 
The polysaccharide polysialic acid (PSA) is a rarely investigated material that has the 
potential to prolong the circulation time of therapeutics in vivo. Unlike PEG, PSA is 
biodegradable and will not accumulate in the human body, causing toxicity [48, 157, 158]. In 
addition, PSA is nontoxic, biocompatible, and non-immunogenic. Studies have shown that some 
pathogenic bacteria were surrounded by the thick PSA coating, which made them “unnoticeable" 
in human body. The thick PSA coating formed a large and highly hydrated structure that could 
help these bacteria evade the host immune system [48, 195, 296, 297]. Based on this, Gregoriadis 
et al. [1, 197] proposed PSA as a potential material for increasing the half-life of therapeutics, 
with the hydrophilic coating preventing interaction between therapeutics and enzymes and 
immune cells. In addition, the PSA coating might decrease the excretion of therapeutics through 
the kidney by increasing the size. A series of studies by Gregoriadis et al. followed this initial 
proposal. Several proteins such as, insulin [6], asparaginase [4, 5] and catalase [2, 3], had been 
either sialylated or polysialylated. PSA was shown to be advantageous with regards to the 
preservation of stability and function, prolongation of circulation time and pharmaceutical effect, 
and reduced immunogenicity and antigenicity [48, 298]. 
Chitosan is a very popular natural polymer for drug delivery because it is nontoxic, 
biodegradable, biocompatible and bioadhesive [32, 299-301]. A quaternized derivative of 
chitosan, N, N, N-trimethyl chitosan (TMC) is soluble and positively charged regardless of pH, 
as opposed to chitosan that possesses a pH-dependent charge. Therefore, TMC has also been 
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widely used [33]. To date, chitosan and its derivatives have been investigated as the basis of 
nanoparticles by many researchers for the delivery of low molecular weight drugs [302], DNA 
[303], proteins and antigens [304]. With the presence of chitosan and/or its derivatives, a number 
of the latter therapeutics have shown higher uptake by diseased tissue, less toxicity and greater 
specificity. 
Despite the advantages given above, the application of chitosan-based nanoparticles is 
limited by poor stability under physiological conditions, poor efficacy in vivo, and a large size 
that is unfavorable for systemic drug delivery [305-309]. Researchers have previously 
demonstrated that 80-120 nm is the ideal size for nanoparticles intended for systemic drug 
delivery [310]. In this size range, nanoparticles can (1) passively accumulate in diseased tissue 
such as inflamed tissue or cancer tissue [252], (2) avoid excretion by the kidneys [13], and (3) 
reduce clearance from the circulation [311]. However, most chitosan-based nanoparticles have a 
size larger than 200 nm, a zeta potential lower than 30 mV, indicative of aggregation under 
physiological conditions, and a large size range, or polydispersity index (PDI) [305-309]. 
Furthermore, due to their cationic nature, chitosan-based nanoparticles are prone to react with 
negatively charged components in the blood circulation, which can increase the rate of clearance 
by the reticuloendothelial system (RES) and phagocytes [312]. Incorporation of highly 
hydrophilic material, such as the polysialic acid used in the current study, can decrease this type 
of interaction and increase the plasma circulation time of the associated drugs [313]. To date, 
few nanoparticles based upon chitosan or its derivatives are ideal for systemic drug delivery due 
to an overly cationic nature, a typically large size and a propensity to aggregate. 
In this study, we developed a PSA-TMC nanoparticle system by complexing positively 
charged TMC with negatively charged PSA. At a weight ratio of 0.5 PSA: 1 TMC, the resultant 
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nanoparticles possessed a favorable size and zeta potential, indicative of a promising drug 
delivery system. To further demonstrate the nanoparticles capacity in drug delivery, 
methotrexate (MTX) a therapeutic used in the treatment of both rheumatoid arthritis and cancer, 
was used as a model compound for encapsulation and controlled release. Cytotoxicity and uptake 
of the nanoparticles was evaluated using a rheumatoid arthritis synovial fibroblast cell line 
(MH7A). In further study, we will investigate the anti-rheumatic effect and bio-distribution of 
this nanoparticle system relative to free MTX. 
5.2 Materials and Methods 
5.2.1 Materials 
Polysialic acid was purchased from Nacalai USA, Inc. (San Diego, CA, USA). Chitosan 
(Mw 100k-300kDa) was purchased from Acros Organics (Fair Lawn, NJ, USA). Sodium 
hydroxide (extra pure, pellets), tripolyphosphate (pure) (TPP), acetonitrile (HPLC grade) were 
also from Acros Organics (New Jersey, USA). Sodium iodide (puriss), methyl iodide (reagent 
plus), 1-methyl-2-pyrrolidinone (anhydrous), ethanol (reagent alcohol), ammonium acetate, 
deuterium oxide, and acetic acid (ACS reagent grade) were obtained from Sigma (St. Louis, MO, 
USA). Hydrochloric acid (ACS plus grade) was supplied by Fisher Scientific (Hanover Park, IL, 
USA). Methotrexate was purchased from Enzo Life Science (Farmingdale, NY, USA). All 
chemical reagents were used without further purification. MH7A synovial fibroblast cell line was 
provided by the Riken BRC through the National Bio-Resource Project of the MEXT, Japan. 
RPMI-1640, D-PBS, HEPES, L-glutamine, fetal bovine serum (FBS) and penicillin-
streptomycin were purchased from Lonza, Inc. (Allendale, NJ). 
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5.2.2 Preparation of Polysialic Acid-N,N,N-Trimethyl Chitosan (PSA-TMC) 
Nanoparticles 
5.2.2.1 Synthesis of N,N,N-Trimethyl Chitosan (TMC) 
The general procedure for TMC synthesis, as well as ionic complexation with TPP to 
form nanoparticles is illustrated in Figure 17. TMC was synthesized according to a one-step 
method, previously described by Sieval et al. [314] Briefly, in a sample procedure, 0.5 g (0.0031 
mol) chitosan and 1.2 g (0.008 mol) sodium iodide were added into 20 ml anhydrous N-methyl 
pyrrolidinone in a nitrogen purged 3-neck flask. The solution was reacted at 60 °C for 1.5 h with 
a stirring speed of 190 rpm. Then, 4.13 ml 1M NaOH (0.0041 mol NaOH), 2.88 ml (0.046 mol) 
methyl iodide were added and stirring was continued for another 1 h at 60 °C. The reaction 
solution was then added dropwise to cold ethanol. The yellow precipitate was collected by 
vacuum filtration. For further purification, the product was dissolved in 15ml DI water and 
precipitated again in 62 ml 1M HCL in ethanol. 0.626 g of white, solid product was obtained 
after vacuum filtration and evaporation overnight in a vacuum oven. The degree of 
quaternization (DQ) of TMC was determined by 1H-NMR (Bruker DPX-300) in D2O. The DQ 
was calculated by the following equation, DQ (%) = [(∫ TM/∫ H) × 1/9] × 100 [315].
 
∫ TM is the 
integral of 1H trimethyl amino group peak at 3.0-3.2 ppm and 
 
∫ H is the integral of 1H peak from 
C1 of the glycoside ring from 4.9 ppm to 5.5 ppm (Figure 39). 
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Figure 17. Synthesis of TMC and complexation with PSA in the presence of TPP to yield 
nanoparticles. 
5.2.2.2 Preparation of PSA-TMC Nanoparticle 
Ten sets of PSA-TMC nanoparticles were prepared by varying the ratio of PSA: TMC or 
the TPP concentration (Table 4). The method was similar to those previously established for 
ionic gelation of chitosan/TMC with TPP [316, 317]. As an example procedure, to prepare PSA: 
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TMC (0.5:1) with a TPP concentration of 0.2mg/ml (Group 3, Table 4), 6.4 mg of TMC was 
dissolved in 3 ml of 0.3% acetic acid in a glass vial. In a separate glass vial, 3.2 mg PSA and 
1mg TPP were mixed well with 2ml deionized (DI) water. The PSA solution was added drop by 
drop to the TMC solution while stirring. The solution was stirred for 30 min to stabilize the 
nanoparticles system. A pellet of nanoparticles was obtained after centrifugation at 300 rpm for 
15 min. Excess supernatant was removed. 
Table 4. Different weight ratios of PSA: TMC and TPP concentrations used in the preparation of 
nanoparticles. 
Group PSA (mg) TMC (mg) 0.3% Acetic Acid (ml) DI Water (ml) TPP (mg) 
1 0 6.4 (Chitosan) 3 2 1 
2 0 6.4 3 2 1 
3 3.2 6.4 3 2 1 
4 6.4 6.4 3 2 1 
5 12.8 6.4 3 2 1 
6 3.2 6.4 3 2 0 
7 3.2 6.4 3 2 0.5 
8 3.2 6.4 3 2 1.5 
9 3.2 6.4 3 2 2 
10 3.2 6.4 3 2 4 
 
5.2.3 Characterization of PSA-TMC Nanoparticles 
The size and zeta potential of the PSA-TMC nanoparticles were measured using a 
Malvern Zetasize NanoZS90 (Malvern Instruments Ltd., Malvern, UK). The particle size 
distribution of the nanoparticles was reported as a PDI. The nanoparticles were dissolved in DI 
water at 2 mg/ml and used without filtration. Then, the nanoparticle solutions were transferred to 
disposable micro-cuvettes (Malvern Instruments Ltd., Malvern, UK) for size measurements and 
disposable capillary cells (Malvern Instruments Ltd., Malvern, UK) for zeta potential 
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measurements. For dynamic light scattering measurements, the temperature was set 25 °C, and 
the scattered light was detected at an angle of 173°. All measurements were performed in 
triplicate. 
Morphological examination of the nanoparticles was performed by atomic force 
microscopy (AFM). A drop of aqueous nanoparticle solution (2 mg/ml) was placed on a thin 
round glass cover slip that was dried in a desiccator overnight. Images were obtained with a 
Nanoscope III atomic force micro- scope (Veeco Instruments Inc., Plainview, NY) in contact 
mode. 
WST-8 assay (Cayman Chemical Company, Ann Arbor, MI) was conducted on the 
MH7A rheumatoid arthritis synovial fibroblast cell line, following the manufacturer's 
instructions, to assess the cytotoxicity of the PSA-TMC nanoparticles. NADH produced within 
the mitochondria reduces WST-8 tetrazolium salt to formazan dye, which can be quantified by 
absorbance measurements at 450 nm. Cells were seeded into 96-well cell culture plate (2 × 104 
cells per well) and cultured for 24 h at 37 °C, 5% CO2. PSA-TMC (0.5:1) was added to yield a 
series of concentrations from 0.3125 mg/mL to ~20 mg/mL, and the cultures were incubated for 
an additional 24 h. 10 µL of WST-8 solution were added to each well. After a 90 min incubation 
period, absorbance was measured with a Synergy 2 multimode micro-plate reader (BioTek 
Instruments, Winooski, VT) at 450nm. The cytotoxicities of TMC and TPP alone, i.e., not 
contained within a nanoparticle, were also evaluated following the above procedure. Untreated 
MH7A synovial fibroblast cultures were used as controls. Relative absorbance versus 
concentration was plotted for each set of additives, and a four parameter logistic, constructed 
with Kaleidagraph software, was used to fit the data to determine the IC50 values. Each 
experiment was repeated independently at least two times. 
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5.2.4 Encapsulation and Release of Methotrexate (MTX)  
5.2.4.1 Encapsulation of MTX 
MTX was encapsulated within PSA-TMC nanoparticles (0.5 PSA: 1 TMC, 0.2mg/ml 
TPP) at a 25% by weight loading percentage. 2.4 mg of MTX was added to the PSA solution, as 
described above. The PSA solution with MTX was added drop by drop to the stirring TMC 
solution to yield MTX loaded nanoparticles. Again, the final solution was stirred for 30 min to 
stabilize the nanoparticle system. MTX loaded nanoparticles were isolated by centrifuging at 
3000 rpm for 15 min. 1 ml supernatant was kept following centrifugation to assess loading 
capacity, while the remaining supernatant was discarded. 
5.2.4.2 Release of MTX from PSA-TMC Nanoparticles 
Release studies were performed on the MTX loaded PSA-TMC nanoparticles. 
Immediately after preparation, nanoparticle solutions were transferred to 15 ml centrifuge tubes 
and centrifuged at 3000 rpm for 15 min. 1 ml of supernatant was saved for the loading capacity 
and efficiency analysis. To begin the release experiments, the nanoparticles were re-suspended in 
5 ml of DI water, and the nanoparticle solutions were transferred to Spectra/Por (Spectrum 
Laboratories, Rancho Dominguez, CA, USA) dialysis tubes (MWCO 12,000-14,000). Dialysis 
was performed against 45 ml DI water pH 7.4, at 37 °C under static conditions. 1 ml of external 
medium was withdrawn and immediately replaced with fresh DI water at the following time 
points: 10min, 20min, 40min, 1, 2, 4, 6, 12, 24 and 48h. The release samples were analyzed with 
a Prominence Ultrafast Liquid Chromatography System (UFLC, Shimadzu Scientific 
Instruments, Japan) equipped with an SPD-20AV UV detector, an SIL- 20A autosampler, a 
  
91 
DGU-20A3 degasser, and a Shim-pack XR-ODS/C8/Phenyl column. The mobile phase was a 
93:7 mixture (v/v) of 50 mM aqueous ammonium acetate and acetonitrile that was pumped at a 
slow rate of 0.5 ml/min. An injection volume of 100 µL was used, and the detection wavelength 
was set to 210 nm. A calibration curve was constructed by determining the area under the peak 
of eight MTX solutions with known concentrations ranging from 0.39 µg/ml to 50 µg/ml using 
PeakFit 4.2 software. Loading capacity (LC) and loading efficiency (LE) were determined using 
the following equations: 
LE = !!"#,!"#$%$!!"#,!""#"  × 100     (5.1) 
LC = !!"#,!"#$%$!!"#$%"&'()*+,            (5.2) 
where mMTX;added is the mass of MTX added to the PSA solution, mMTX;loaded is the mass of MTX 
loaded into the nanoparticles, and mNanoparticle is the mass of the nanoparticles used for the release 
study. 
5.2.5 Cellular Uptake of PSA-TMC Nanoparticles 
Uptake of the PSA-TMC nanoparticles by the MH7A cells was verified with inverted 
fluorescence microscopy. The MH7A cells were added to lysine coated Lab-Tek® Chamber 
Slides, and fluorescently tagged nanoparticles (Alexa Fluor®
 
610, Invitrogen) were added 24 h 
after seeding. After a short incubation period (~45 min), the nanoparticle solution was removed, 
the cells were washed with PBS, and uptake was observed with a Nikon Eclipse Ti inverted 
microscope. The incubation period was selected based on prior optimization experiments and is 
consistent with other researchers with regards to the short time necessary to observe uptake of 
  
92 
chitosan-based nanoparticles [318-320]. 
5.3 Results and Discussions 
5.3.1 Nanoparticle Synthesis and Characterization 
From the 1H NMR spectra, a DQ of ~50% was reproducibly obtained (Figure 39). 
Jintapattanakit et al [321] reported that, at this DQ range, TMC has higher water-solubility and 
mucoadhesiveness. The DQ determined the amount of positive charge in chitosan chains. This 
consequently had a significant impact on the surface charge of the nanoparticles, which 
indirectly related to the size distribution of the nanoparticles due to aggregation. Therefore, to 
produce TMC with a reproducible DQ of 50% was critical in obtaining reproducible 
nanoparticles with consistent size distribution [33]. 
In this study, three different weight ratios of PSA: TMC were investigated, all prepared 
with a TPP concentration of 0.2 mg/ml. Chitosan and 50% modified TMC, with no PSA, were 
used as controls. The results were summarized in Figure 18. As indicated by zeta potential values 
much less than an absolute value of 30, PSA: TMC nanoparticles with weight ratios of 1:1 and 
1:2 were not stable. Low zeta potential values were associated with a deficiency of electronic 
force necessary to keep the nanoparticles separated from each other [233]. Chitosan itself did 
form particles, consistent with other researchers [322]; however, the size was not favorable for 
drug delivery. Furthermore, the size variation and size distribution were high, suggestive of a 
lack of stability and a propensity to aggregate [24]. Presumably, the variability in size with a 
high PDI was a result of the pH-dependent positive charge. In contrast, pH-independent TMC 
formed nanoparticles with the desired size; however, the size distribution remained high. In 
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addition, the lack of a hydrophilic component, such as PSA, might result in undesirable uptake 
by the RES during circulation [37]. A PSA: TMC ratio of 0.5:1 was identified as the only ratio 
that gave rise to nanoparticles with favorable size, a size distribution that was significantly 
	  
Figure 18. (A) Size, (B) zeta potential, and (C) PDI as a function of the weight ratio of PSA: 
TMC. *p < 0.05 relative to CH, 1 PSA:1 TMC, and 2 PSA:1 TMC.   
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lower than other formulations, and an appropriate surface charge for systemic drug delivery. 
To investigate the effect of TPP concentration size distribution, five different TPP 
concentrations were investigated for nanoparticles prepared with a 0.5:1 PSA: TMC ratio (Figure 
19). Nanoparticles prepared with no TPP were used as controls. At 0.1 mg/ml and 0.2 mg/ml 
TPP, the resultant nanoparticles were of an appropriate size with a narrow size distribution. As 
TPP concentration increased, the size of the resultant nanoparticles and size distribution became 
larger; however, the differences between nanoparticles prepared with 0.1 mg/ml, 0.2 mg/ml, 0.3 
mg/ml and 0.4 mg/ml were not significant. As shown by the zeta potential values, an increasing 
amount of TPP increased the negative charge of the nanoparticles, thereby neutralizing the 
positive charge of the TMC. This reduction in nanoparticle surface charge could in turn be linked 
to an increase in the interaction between the nanoparticles, resulting in particles with larger sizes 
and size distributions. PSA complexed with TMC in the absence of TPP yielded nanoparticles of 
the appropriate size; however, the PDI was significantly larger than those prepared with  
0.1 mg/ml and 0.2 mg/ml TPP. A literature survey indicated that nanoparticles prepared with 
higher TPP concentrations possess a greater crosslink density [49-51]; therefore, a 0.2 mg/ml 
TPP concentration would presumably yield nanoparticles with enhanced stability, slower release 
kinetics and increased loading efficiency relative to a 0.1mg/ml TPP concentration. Based upon 
this premise and results described herein, a 0.5:1 ratio of PSA: TMC with a TPP concentration of 
0.2 mg/ml was identified as the ideal formulation for the formation of stable nanoparticles. A 
small size, with narrow distribution, and a spherical morphology were confirmed by AFM 
(Figure 20). AFM has been proven to be an ideal method for nanoparticle characterization, 
allowing for visualization in three dimensions [52, 53]. Although a strong surface-tip interaction 
might cause image distortion, this did not appear to occur with the PSA-TMC nanoparticles. 
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Figure 19. (A) Size, (B) zeta potential, and (C) PDI as a function of TPP concentration 
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Figure 20. AFM image of PSA-TMC nanoparticles (0.5 PSA:1 TMC, 2 mg/ml TPP). 
5.3.2 Encapsulation and Controlled Release of MTX 
MTX was successfully encapsulated into the PSA-TMC nanoparticles with a loading 
efficiency and loading capacity of 46.3 ± 13.0% and 0.10 ± 0.03 mg MTX/mg nanoparticle, 
respectively. Dynamic light scattering was used as an additional indicator to verify MTX 
encapsulation. Although the difference was not significant, the MTX loaded nanoparticles were 
slightly larger than the unloaded nanoparticles (128.7 ± 5.3 versus 106.3 ± 25.4) (Figure 21). 
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Figure 21. Size of MTX loaded nanoparticles. 
Fractional release of MTX as a function of time from the PSA-TMC nanoparticles is 
shown in Figure 22. Although controlled release was observed, the data could not be fit to a 
simple diffusion controlled model, where the fractional release was proportional to the square 
root of time. Consistent with other hydrophobic drugs encapsulated into nanoparticles at high 
loading capacity (≥ 0.30), the release was presumably dissolution controlled [323]. An in depth 
analysis on the mechanism and kinetics of release, as well as the in vitro efficacy of encapsulated 
therapeutics, will be the topic of future studies. 
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Figure 22. Fractional release of methotrexate from PSA-TMC nanoparticles (0.5 PSA: 1 TMC, 2 
mg/ml TPP) as a function of time 
5.3.3 Cytotoxicity 
For future applications in diseases such as rheumatoid arthritis where the primary goal is 
not cell death, the cytotoxicity of the nanoparticles must be minimal. As shown in Table 5, TMC 
had some cytotoxicity as anticipated based on reports by others on the impact of chitosan 
quaternization on biocompatibility [321]. Previous research from our lab had demonstrated that 
PSA was not cytotoxic [253], and incorporation of TMC into nanoparticles with PSA resulted in 
significantly higher IC50 values than TMC alone. The TMC should be released from the 
nanoparticle at a slow rate that would yield only negligible levels of this potentially harmful 
polymer when administered in vivo. Somewhat surprising was the extremely low IC50 value 
observed for TPP given the prevalent use of TPP in forming chitosan TMC nanoparticles. Most 
recent studies have not tested (1) the cytotoxicity of TPP alone or (2) the cytotoxicity of the 
chitosan-TPP system as a whole based on the assumption that chitosan is nontoxic [301, 324, 
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325]. Despite this oversight, a manuscript was recently published on the use of TPP as an 
excipient that clearly demonstrated the concentration-dependent cytotoxicity of TPP [326]. 
Exclusion of TPP did reduce the cytotoxicity further (data not shown); however, the TPP was 
presumably necessary to maintain particle stability (Figure 19). 
Table 5. IC50 values for TMC, TPP, and PSA-TMC nanoparticles 
 IC50 (mg/ml) 
TMC 2.30 ± 0.84 
TPP 0.22 ± 0.04 
Nanoparticles (0.5 PSA: 1 
TMC) 
7.65 ± 0.07 
 
5.3.4 Internalization of Nanoparticles by MH7A Cells 
To confirm that the PSA-TMC nanoparticles could be internalized by cells in the absence 
of an active targeting moiety that would facilitate receptor-mediated endocytotic uptake, the 
nanoparticles were surface modified with a near infrared fluorescent tag and incubated with the 
MH7A rheumatoid arthritis synovial fibroblast cell line. As illustrated in Figure 23, even after 
only a short incubation period, the nanoparticles were able to successfully associate with and 
enter the cells. The results coincided with the known interactions that occurred between 
chitosan/chitosan-based materials and cellular membranes [324, 327-329]. 
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Figure 23. Relative to (A) control cells, (B) fluorescently tagged nanoparticles were readily 
internalized by MH7A cells 
5.3.5 Comparison to Other MTX-Loaded Nanoparticles 
Although numerous studies have been conducted with regards to the 
encapsulation/release of MTX in/from nanoparticles [327-334], most have been designed for the 
treatment of cancer, where the goal is to maintain or optimize the cytotoxicity that can be 
achieved with high doses of methotrexate. In contrast, effective carrier systems for the delivery 
of low, anti-inflammatory doses of methotrexate for the treatment of diseases that require long 
term care, such as rheumatoid arthritis, must be non-immunogenic and non-cytotoxic. Thus far, 
only a few systems have been designed with the latter goal in mind. 
Two investigators have provided in vivo evidence with arthritis rat models that the 
efficacy of MTX in the treatment of rheumatoid arthritis could be improved by association with 
or conjugation to a carrier system. Encapsulation of MTX into phospholipid nanoparticles 
yielded a greater reduction in inflammation than free MTX [334]; however, the utility of this 
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carrier system for systemic administration, as is requisite for rheumatoid arthritis, has not yet 
been determined. Alternatively, MTX conjugated to poly(amidoamine) (PAMAM) dendrimer 
nanoparticles proved to be highly effective for targeted delivery to inflamed joints when 
administered intravenously [332]. PAMAM dendrimers were significantly smaller than the PSA-
TMC nanoparticles, thus the two carrier systems would likely exhibit different pharmacokinetic 
profiles. In addition to the latter in vivo studies, Jingou et al. prepared and characterized 
chitosan/cyclodextrin nanoparticles with the goal of simultaneously delivering 
hydrophilic/hydrophobic drugs for the treatment of rheumatoid arthritis. MTX was used as the 
model hydrophobic compound [333]. Relative to the work described herein, Jingou’s 
nanoparticles were less effective at entrapping MTX, and the MTX release rate from the Jingou’s 
nanoparticles was faster. In addition, the large size of Jingou’s nanoparticles was not appropriate 
for effective systemic delivery. The limited examples of existing carrier systems have 
highlighted the need for continued expansion of the field of drug delivery into the treatment of 
chronic diseases such as rheumatoid arthritis. 
5.4 Conclusion 
The nanoparticle is a type of drug delivery system that can facilitate selective 
accumulation of drugs in diseased areas. For systemic drug delivery, these nanoparticles systems 
must possess a long circulation time to have merit. In this study, we reported a gel nanoparticle 
system with a size of 106 ± 25 nm formed by ionic gelation between PSA and TMC in a ratio 
0.5:1 (w/w) in the presence of TPP (0.2 mg/ ml). We believe that the highly hydrophilic PSA 
chains would significantly prolong circulation time compared to other chitosan-based systems. 
  
102 
MTX was chosen as the model drug in this study because of our interest in improving treatment 
strategies for rheumatoid arthritis sufferers. Future studies will be used to specifically address the 
potential for the MTX loaded nanoparticles to treat rheumatoid arthritis. 
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Chapter 6 In Vitro Efficacy of Polysaccharide-Based 
Nanoparticles Containing Disease-Modifying Anti-
rheumatic Drugs  
Purpose: To evaluate the therapeutic efficacy of dexamethasone (DM) and methotrexate (MTX) 
entrapped within polysialic acid (PSA)-N, N, N-trimethyl chitosan (TMC) nanoparticles using an 
in vitro model of rheumatoid arthritis (RA).  
Methods: The loading capacity of the PSA-TMC nanoparticles was determined. A RA in vitro 
model was developed by stimulating a synovial cell line with a pro-inflammatory mediator. 
Multiplex immunoassay was used to determine changes in the secretion of interleukin-6 (IL-6), 
interleukin-8 (IL-8), and granulocyte-macrophage colony-stimulating factor (GM-CSF) by the in 
vitro model following administration of the DM- and MTX-loaded nanoparticles.   
Results: The loading capacity of the PSA-TMC nanoparticles was approximately 0.1 mg of 
drug/mg of nanoparticle. When applied to our in vitro model of RA, there were no significant 
differences in the concentrations of any of the pro-inflammatory mediators when comparing the 
free drugs and drug-loaded nanoparticles, administered at concentration of 0.1 mg/ml and 1.0 
mg/ml, respectively.  
Conclusions: The present study verified that MTX- and DM-loaded nanoparticles possess 
therapeutic efficacies that are nearly equivalent to those of the free drugs. The demonstrated in 
vitro efficacy is expected to translate to in vivo success when the PSA-TMC nanoparticles are 
used to enhance targeting of the inflamed tissue.  
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ABBREVIATIONS 
DM   Dexamethasone 
DMARD  Disease-Modifying Anti-rheumatic Drug 
GM-CSF  Granulocyte-Macrophage Colony-Stimulating Factor 
IL-1β    Interleukin-1β  
IL-6   Interleukin-6   
IL-8    Interleukin-8     
MTX   Methotrexate 
PSA   Polysialic Acid 
RA   Rheumatoid Arthritis 
TMC   N, N,N-Trimethyl chitosan 
TPP   Tripolyphosphate 
6.1 Introduction 
Conventional therapeutics for rheumatoid arthritis (RA) are plagued by unpredictable 
pharmacokinetic profiles and non-specific organ toxicity [274, 335]. To overcome these 
problems, nanocarriers have been proposed to increase a drug’s circulatory stability and thereby 
raise the probability of passive accumulation within regions of enhanced permeability, 
particularly inflamed tissue.  
 A lack immunogenicity, as well as non-cytotoxicity, are requisite properties for materials 
used in RA drug delivery. Polysaccharides are a logical, versatile choice for the formation of 
biodegradable, non-immunogenic nanoparticles. Due to variations in chemical composition, 
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polysaccharides exhibit overall neutral, negative, or positive charge states. In addition, the 
macromolecular chains possess a number of functionalities, particularly amines, hydroxyl 
groups, and carboxylic acids that are easily amenable to modification [336].  Although a number 
of polysaccharides have been explored, chitosan is the most used polysaccharide to generate 
nanoparticles for drug delivery [337]. Often, the cationic nature of the polymer resultant from 
free or quaternized primary amines is used for ionic crosslinking through a polyanion 
crosslinker, such as tripolyphosphate (TPP) [338-341]. Chitosan can also be ionically complexed 
with negatively charged natural polymers, such as hyaluronic acid, alginate, heparin, peptides, 
and nucleic acids.[336]  
As previously reported, our lab has developed nanoparticles via ionic complexation of N, 
N, N-trimethyl chitosan (TMC) and polysialic acid (PSA), a polysaccharide never before used in 
nanoparticle formation protocol [342] . By incorporating PSA, nanoparticles are obtained with a 
smaller size relative to chitosan and TMC nanocarrier systems developed previously. Similar to 
poly (ethylene glycol), PSA functions to prevent undesirable uptake by the reticuloendothelial 
system, thereby extending circulatory stability and facilitating passive accumulation of 
associated therapeutics within areas of leaky vasculature, such as tissue affected by RA [48, 198, 
199].  
This study aims to verify that two disease-modifying anti-rheumatic drugs (DMARDs), 
methotrexate (MTX) and dexamethasone (DM), are therapeutically effective when entrapped 
within the previously developed PSA-TMC nanoparticles. The chosen therapeutics have highly 
variable pharmacokinetic profiles in RA patients and are associated with adverse side effects 
[274, 343, 344]. MTX- and DM-loaded nanoparticles were administered to an in vitro model of 
RA generated from interleukin-1β (IL-1β) activated SW-982 synovial cells. Following treatment 
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of the in vitro model for 24 hours, the concentrations of the following pro-inflammatory proteins 
within the supernatant were evaluated using multiplex immunoassay on the Luminex® Platform:  
interleukin-6 (IL-6), interleukin-8 (IL-8), and granulocyte-macrophage colony-stimulating factor 
(GM-CSF). The three proteins chosen are representative of the pro-inflammatory cytokines, 
chemokines, and growth factors that are upregulated in those that suffer from RA [345, 346].  
6.2 Materials and methods 
6.2.1 Materials 
Polysialic acid (PSA) was purchased from Nacalai USA, Inc. (San Diego, CA, USA). 
Sodium hydroxide (extra pure, pellets), sodium tripolyphosphate (pure, TPP), acetonitrile (HPLC 
grade), and chitosan (Mw 100 Da - 300 kDa) were obtained from Acros Organics (New Jersey, 
USA). Sodium iodide (puriss), methyl iodide (reagent plus), 1-methyl-2-pyrrolidinone 
(anhydrous), ethanol (re- agent alcohol), ammonium acetate, deuterium oxide, and acetic acid 
(ACS reagent grade) were procured from Sigma (St. Louis, MO, USA). Hydrochloric acid (ACS 
plus grade) was acquired from Fisher Scientific (Hanover Park, IL, USA). Methotrexate (MTX) 
and dexamethasone (DM) were purchased from Enzo Life Science (Farmingdale, NY, USA). All 
chemical reagents were used without further purification.  
6.2.2 Cell Culture 
The SW-982 human synovial sarcoma cell line was acquired from ATCC (Manassas, 
VA). Dulbecco’s Modified of Eagle’s Medium (DMEM) supplemented with 4.5 g/L glucose, L-
glutamine & sodium pyruvate was procured from Mediatech, Inc. (Manassas, VA). Fetal bovine 
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serum (FBS) and penicillin-streptomycin were purchased from Lonza, Inc. (Allendale, NJ). 
Sulforhodamine 101 cadaverine was obtained from Anaspec (Fremont, CA).  
6.2.3 Preparation and Characterization of DMARD-Loaded PSA-TMC 
Nanoparticles 
Drug-loaded PSA-TMC nanoparticles were prepared from PSA and TMC (55% degree of 
substitution) following a previously published protocol [347]. Briefly, 6.4 mg of TMC were 
dissolved in 3 ml of 0.3% acetic acid in a glass vial. In a separate glass vial, 3.2 mg PSA, 1mg 
TPP, and 2.4 mg MTX or DM were mixed well in 2 ml of DI water. The PSA solution was 
sonicated for 10 min and then added drop-wise to the TMC solution with stirring. Stirring was 
continued for 30 min to ensure nanoparticle formation. The solution was centrifuged at 1000 rpm 
for 5 min to remove non-encapsulated drugs. The supernatant was collected and centrifuged for 
an additional 15 min at 3000 rpm to obtain MTX- or DM-loaded nanoparticles as a white pellet. 
Identical to the procedure previously described for MTX [347], an Ultrafast Liquid 
Chromatography System (UFLC, Shimadzu Scientific Instruments, Japan) equipped with an 
SPD-20AV UV detector, an SIL- 20A autosampler, a DGU-20A3 degasser, and a Shim-pack 
XR-ODS/C8/Phenyl column was used to quantify the amount of DM that was not encapsulated, 
which allowed for assessment of  the DM loading properties of the nanoparticles. The mobile 
phase was a 70:30 mixture (v/v) of water: acetonitrile, and the detection wavelength was set to 
238 nm. A calibration curve were constructed by using PeakFit 4.2 software to determine the 
area under the peak of at least five known concentrations of free drug in the mobile phase 
ranging from 0.39 mg/L to 100 mg/L. Loading efficiency (LE) and loading capacity (LC) were 
determined with the following equations:  
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LE = 
!!"#  !"  !",!""#"  !  !!"#  !"  !",!"#"$%&'!(%)#*!!"#  !"  !",!""#"  × 100     (6.1) 
LC = 
!!"#  !"  !",!""#"  –  !!"#  !"  !",!"#"$%&'!(%)#*!!"#$%"&'()*+!             (6.2) 
where mDM,added is the mass of DM added to the PSA solution, mDM,unencapsulated is the mass of DM 
that has not been encapsulated into the nanoparticles, and mNanoparticles is the mass of the 
nanoparticles used for DM loading. 
The size and zeta potential of DMARD-loaded PSA-TMC nanoparticles were measured 
via a Malvern Zetasize NanoZS90 (Malvern Instruments Ltd., Malvern, UK). The size 
distribution of nanoparticles was reported as the polydispersity index (PDI). Nanoparticles were 
suspended in deionized water at a concentration 2 mg/ml and transferred into disposable 
microcuvettes (Malvern Instruments Ltd., Malvern, UK) for size measurements and disposable 
capillary cells (Malvern Instruments Ltd., Malvern, UK) for zeta potential measurements. For 
dynamic light scattering, the temperature was set to 25ºC and scattered light was detected at 
173º. All measurements were performed triplicate. 
6.2.4 In Vitro Cytotoxicity of Nanoparticles 
WST-8 assay (Cayman Chemical Company, Ann Arbor, MI) was conducted on the SW-
982 cell line, following the manufacturer's instructions, to assess the cytotoxicity of the drug-
loaded nanoparticles. Cells were seeded into a 96-well cell culture plate (2 × 104 cells per well) 
and were cultured with DMEM plus 10% FBS for 24 h at 37 °C, 5% CO2. Following sterile 
filtration, drug-loaded nanoparticles were added to yield a series of concentrations from 0.3125 
mg/mL to 20 mg/mL, and the cultures were incubated for an additional 24 h. 10 µL of WST-8 
solution and 100 µL media were then added to each well. After a 90 min incubation period, 
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absorbance was measured with a Synergy 2 multimode microplate reader (BioTek Instruments, 
Winooski, VT) at 450 nm. The cytotoxicities of free TMC, and TMC-PSA nanoparticles without 
drug were also evaluated. IC50 values were determined using the Hill slope model with 
Kaleidagraph software. Each experiment was repeated independently at least three times. 
6.2.5 Cellular Uptake of Nanoparticles In Vitro 
SW982 cells were seeded onto lysine coated 35 mm Glass Bottom Culture Dishes 
(MatTek Corporation, Ashland, MA) at a density of 1 million cells/dish. After a 24 h incubation 
period in DMEM plus 10% FBS at 37 °C and 5% CO2, the media was removed, and sterile-
filtered, fluorescently labeled (sulforhodamine 101 cadaverine) PSA-TMC nanoparticles in 1X 
PBS were added. Media from the control cells that did not receive nanoparticles was 
simultaneously replaced with PBS. Cells were incubated for an additional 60 min at room 
temperature and washed with PBS three times before imaging with a Nikon Eclipse Ti inverted 
microscope to observe nanoparticle internalization. 
6.2.6 In Vitro Assessment of Bioactivity 
SW-982 cells were seeded into a 96-well cell culture plate (5000 cells/well) in the 
presence of a pro-inflammatory simulant, interleukin-1β (IL-1β) (R&D Systems, Minneapolis, 
MN), at a concentration of 1 ng/mL. The low concentration of the stimulating agent was able to 
induce a significant pro-inflammatory response from synovial cells, consistent with previous 
studies [348-351]. After 24 h of incubation, MTX or DM loaded nanoparticles were added to the 
IL-1β stimulated cells following sterile filtration. Prior to addition, the MTX- or DM-loaded 
nanoparticles were suspended in DMEM plus 10% FBS at a concentration of 1.0 mg/ml. Control 
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groups included stimulated cells without treatment, stimulated cells with addition of free 
(unloaded) nanoparticles, and stimulated cells with 0.1 mg/mL or 1.0 mg/ml DMARD. After 24 
h, culture supernatant was collected and stored in aliquots at -80 °C until pro-inflammatory 
protein analysis. Supernatant samples were analyzed for pro-inflammatory proteins (IL-6, IL-8, 
and GM-CSF) using a Bio-Plex Precision Pro human cytokine assay panel (BIO-RAD, Hercules, 
CA) on a Luminex® 200 system (Austin, TX) following a manufacturer-provided protocol. Each 
experiment was repeated independently at least three. 
6.2.7 Data Analysis 
Proteins levels were expressed relative to those obtained from untreated control cells. 
Data is presented as the mean ± standard deviation (N ≥ 3). All treatment groups (control, 0.1 
mg/mL MTX or DM, 1.0 mg/mL MTX or DM, MTX- or DM- loaded nanoparticles, free 
nanoparticles) were compared by one-way ANOVA with Fisher’s LSD post hoc tests. p < 0.05 
was considered to be significant. 
6.3 Results 
6.3.1 Preparation and Characterization of DMARD-Loaded PSA-TMC 
Nanoparticles 
The loading efficiency and loading capacity of PSA-TMC nanoparticles for DM were 
determined to be 41.3 ± 7% and 0.01 ± 0.02 mg DM/mg nanoparticles, respectively. The values 
were comparable to those previously obtained in the preparation of MTX-loaded PSA-TMC 
nanoparticles (LE = 46.3 ± 13%, LC = 0.10 ± 0.03 mg MTX/mg nanoparticles) (Table 6) [347].  
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Likewise, as provided in Table 7, the size of DM-loaded nanoparticles was slightly 
greater than that previously observed for free nanoparticles and comparable than that determined 
for MTX-loaded nanoparticles. All of the nanoparticle formulations yielded a low 
polydispersityand a zeta potential value greater than 30 mV. The slight increase in size, in 
conjunction with the lack of an observable effect on zeta potential, suggested that the DMARDs 
were being entrapped within the nanosized carriers, as expected. 
Table 6. Load efficiency and loading capacity of MTX and DM by PSA-TMC nanoparticles 
(NPs) 
 LE LC(mg drug/mg nanoparticles) 
MTX-loaded NPs 46.3 ± 13% 0.10 ± 0.03 
DM-loaded NPs 41.3 ± 7% 0.10 ± 0.02 
Table 7. Size, zeta potential, and polydispersity of NPs and MTX or DM-loaded NPs 
 Size (nm) Zeta potential (mV) PDI 
NPs 102.2 ± 14.5 33.4 ±1.6 0.12 ± 0.02 
MTX-loaded NPs 128.7 ± 5.3 32.7 ± 0.9 0.10 ± 0.02 
DM-loaded NPs 120.7 ± 11.1 34.8 ± 2.5 0.12 ± 0.02 
6.3.2 In Vitro Cytotoxicity of Drug–Loaded and Plain Nanoparticles 
As summarized Table 8 with the calculated IC50 values, the free and DMARD-loaded 
nanoparticles were non-cytotoxic up to high concentrations. Consistent with our prior study 
using MH7A synovial cells rather than SW-982 cells, the inherent cytotoxicity of quaternized 
chitosan was significantly reduced upon complexation with PSA to form nanoparticles. Of note, 
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the IC50 value for the PSA-TMC nanoparticles did not change with DMARD loading, providing 
evidence that MTX and DM did not induce a cellular response by impacting cellular 
proliferation.  This result supported prior research showing that free MTX and DM did not 
impact cellular proliferation over the range of therapeutic concentrations tested. 
Table 8. IC50 value of TMC, PSA-TMC NPs, MTX-loaded PSA-TMC NPs, and DM-loaded 
PSA-TMC NPs. * indicated a significant difference versus TMC (N=3, P<0.05) 
 IC50 (mg/ml) 
TMC 5.16 ± 0.20 
PSA-TMC NPs 15.82 ± 1.44 * 
MTX-loaded PSA-TMC NPs 14.20 ± 1.20 * 
DM-loaded PSA-TMC NPs 16.01 ± 0.42 * 
                                                                                                                                                                    
6.3.3 Cellular Uptake of Nanoparticles In Vitro 
By modifying PSA with a red fluorescent tag prior to nanoparticle formation, uptake of 
the PSA-TMC cells by synovial SW982 cells could be observed with the aid of a fluorescent, 
inverted microscope. As illustrated in Fig. 24, the nanoparticles were associated within the cells 
following a short incubation period (~60 minutes).  
  
113 
	  
Figure 24. Color composite of fluorescence microscopy images demonstrating nanoparticle 
uptake at room temperature by human synovial sarcoma SW982 cells. To facilitate fluorescence 
microscopic evaluation, PSA was conjugated to sulforhodamine 101 cadaverine. Use of identical 
imaging settings permited direct comparison of fluorescence intensities. Higher intensities 
indicated more cellular uptake of nanoparticle by cells. Left image: cells not incubated with 
nanoparticles resulted in negligible signal. Right image: cells incubated with nanoparticles and 
showed active cellular uptake. Both groups were incubated for 60 min and washed three times 
with PBS before imaging. 
6.3.4 In Vitro Assessment of Bioactivity 
 MTX-loaded nanoparticles significantly suppressed IL-8 secretion relative to the 
untreated control group (Fig. 25). The amount of IL-8 suppression was comparable to that 
achieved with low concentration (0.1 mg MTX/ml) and high concentration (1.0 mg MTX/ml) 
MTX treatment. Low and high concentration MTX treatment also showed significant inhibition 
of GM-CSF secretion but not IL-6 secretion. The nanoparticles alone, in contrast, significantly 
increased GM-CSF secretion, although this effect was eradicated through incorporation of MTX. 
Low and high concentration free MTX treatment additionally resulted in significant inhibition of 
IL-6 and GM-CSF secretion relative free nanoparticle treatment. High concentration MTX 
Control                                   PSA-TMC   
10	  μm 
 -   
 
 
 
 
 
 
 
 
10 µm 
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treatment also led to a significant decrease in IL-6 levels relative to levels obtained with MTX-
loaded nanoparticle treatment. Of note, the raw data showed that the detected concentrations of 
GM-CSF (<<100 pg/ml) were low and close to the limit of detection.    
 
Figure 25. Relative protein secretion (black: GM-CSF; grey: IL-6; dark grey: IL-8) of IL-1β-
stimulated SW-982 cells after treatment with free nanoparticles (NP) at a concentration of 1.0 
mg/ml, free MTX at a concentration of 0.1 mg/ml (0.1 MTX), free MTX at a concentration of 
1.0 mg/ml (1.0 MTX), and MTX-loaded nanoparticles at a concentration of 1.0 mg/ml (NP + 
MTX). The dashed line at a relative concentration of 1 was intended to serve as a point of 
reference for unstimulated control cells. * indicated a significant difference versus untreated 
control cells (p < 0.05); ‡ indicated a significant difference versus free nanoparticles (p < 0.05); 
and § indicated a significant difference versus MTX-loaded nanoparticles (p < 0.05).  
DM-loaded nanoparticles significantly suppressed IL-6 and IL-8 secretion relative to the 
untreated control group and had comparable efficacy to low concentration (1 mg DM/ml) and 
high concentration (1.0 mg DM/ml) free DM treatment (Fig. 26). Furthermore, although there 
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was no significant difference from the control, treatment with DM-loaded nanoparticles, low 
concentration free DM, and high concentration free DM resulted in significantly lower GMC-SF 
levels relative to treatment with free nanoparticles.   
 
Figure 26. Relative protein secretion (black: GM-CSF; grey: IL-6; dark grey: IL-8) of IL-1β-
stimulated SW-982 cells after treatment with free nanoparticles (NP) at a concentration of 1.0 
mg/ml, free DM at a concentration of 0.1 mg/ml (0.1 DM), free DM at a concentration of 1.0 
mg/ml (1.0 DM), and DM-loaded nanoparticles at a concentration of 1.0 mg/ml (NP + DM). The 
dashed line at a relative concentration of 1 was intended to serve as a point of reference for 
unstimulated control cells. * indicated a significant difference versus untreated control cells (p < 
0.05); ‡ indicated a significant difference versus free nanoparticles (p < 0.05); and § indicated a 
significant difference versus DM-loaded nanoparticles (p < 0.05).  
6.4 Discussion  
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MTX is known to be hepatotoxic and patients undergoing treatment must receive periodic 
liver function tests [352, 353]. Likewise, long-term use of DM is associated with severe side 
effects, including insulin resistance and osteoporosis [354]. The drawbacks associated with these 
DMARDs can be attributed to low solubility, unpredictable pharmacokinetics, and non-site 
specific distribution within the body [352, 353] [354]. As explain in depth our prior study on the 
development of PSA-TMC nanoparticles, the sizes and zeta potentials obtained for DMARD-
loaded nanoparticles were expected to minimize accumulation within healthy tissue, reduce 
undesireable uptake by the reticuloendothelial system, and facilitate delivery to the inflamed 
tissue by exploiting the leaky vasculature that characterizes RA. The nanoparticles also 
facilitated controlled release of DMARD over a 24 hour period [347]. In the current study, an in 
vitro model of RA based upon IL-1β activated synovial fibroblasts, the so-called conductors of 
joint destruction [355, 356], was used to demonstrate the therapeutic efficacy of the DMARD-
loaded carrier systems.  
While some toxicity is permissible in carrier systems designed for cancer therapy, the 
primary goal of inflammation reduction in RA treatment demands minimal toxicity.  Consistent 
with our previous studies using the MH7A synovial fibroblast cell line [347], the PSA-TMC 
nanoparticles showed negligible cytotoxicity towards the synovial SW982 cell line over a range 
of concentrations.  The SW982 cell line was used in lieu of the MH7A cell line in the current 
study due to evidence suggesting that the MH7A cell line might not accurately mimic the 
cytokine profile observed RA [351]. Furthermore, the SW982 cell line was shown accurately 
mimic expression of the pro-inflammatory mediator associated with rheumatoid arthritis, 
including IL-6 and IL-8, particularly after stimulation with IL-1β [348-350]. Loading of MTX 
and DM had a negligible impact on the IC50 values, indicating that any change in the secretion of 
  
117 
pro-inflammatory mediators would be due to cellular response rather than apoptosis. A 
concentration of 1 mg/ml was used for in vitro studies to ensure an observable response without 
impacting cellular viability. As illustrated in Fig.24, the PSA-TMC nanoparticles were 
internalized by SW-982 cells.  The results confirmed the potential for intracellular delivery of 
therapeutics via PSA-TMC nanoparticles.  
Changes in the secretion of IL-6, IL-8, and GM-CSF by the activated SW982 cells were 
used to demonstrate the therapeutic efficacy of the DMARD-loaded nanoparticles relative to the 
free drugs (Figs. 25, 26). IL-6, IL-8, GM-CSF were selected as representative cytokines, 
chemokines, and growth factors, respectively.  A literature survey suggested that the three 
chosen proteins were critical to the pathogenesis of rheumatoid arthritis [346]. IL-6 was involved 
in in immune regulation, inflammation, and hematopoiesis. More specifically, IL-6 was thought 
to simulate T and B cells [346, 357], activate osteoclasts [358], and induce expression of 
vascular endothelial growth factor (VEGF) [357], which subsequently triggered the angiogenesis 
that, in part, characterized rheumatoid arthritis. IL-8 stimulated the migration of inflammatory 
cells into the synovium; activated synovial fibroblasts via an autocrine mechanism to induce 
secretion of additional pro-inflammatory mediators; and promoted angiogenesis [359, 360]. GM-
CSF recruited and activated inflammatory cells, particularly T-cells, while also inhibiting 
differentiation of osteoclasts [346] . DMARDs, including those used in the current study, had 
been shown to reduce the secretion of the select pro-inflammatory mediators, thereby disrupting 
the pro-inflammatory network associated with rheumatoid arthritis.   
Of note, although MTX was previously used as a model compound to demonstrate the 
ability of the nanoparticles to encapsulate and release DMARDs [347], DM, in addition to MTX, 
was used to observe therapeutic efficacy . While the anti-inflammatory impact of DM when used 
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in vitro has been well demonstrated, in vitro administration of MTX has yielded highly variable 
responses. Although MTX was as a folate antagonist in the treatment of cancer, the mechanism 
of action for MTX in the treatment of RA was unclear [361-363] and the inconsistencies in in 
vitro response reflect this lack of understanding. Alterations in the cytokine milieu might not be a 
direct result of MTX administration[364]. In contrast, DM was known to reduce inflammation in 
the same manner as other glucocorticoids, where by binding to a glucocorticoid receptor (GR) 
directly impacted the activity of activator protein-1 (AP-1) and nuclear factor kappaB (NF-κB) 
[365]. The latter transcription factors have been definitively linked to the expression and 
secretion of most pro-inflammatory cytokines and chemokines, including IL-6, IL-8, and GM-
CSF [366-368].  
When applied to our in vitro model of RA, the DM- and MTX-loaded nanoparticles, as 
well as the free DMARDs, yielded significant reductions in the secretion of IL-8 relative to the 
control, while only DM (free or encapsulated within nanoparticle) led to significantly decreased 
IL-6 levels relative to the control. In contrast, MTX (free and encapsulated) did not affect IL-6 
concentrations relative to the control group, although significant differences were observed 
comparing treatment with free nanoparticles to free DMARDs. The latter results were reflective 
of the potential differences in the mechanism of action of MTX and DM, as noted above. The 
variable results obtained for GM-CSF, with only free MTX yielding a significant decrease in 
GM-CSF levels, could be attributed to the increased uncertainty in measured concentrations near 
the limit of detection.  More important than comparisons to the control and free nanoparticle 
groups, there were no significant differences in the concentrations of any of the pro-
inflammatory mediators when comparing the free DMARDs and DMARD-loaded nanoparticles, 
administered at concentration of 0.1 mg/ml and 1.0 mg/ml, respectively. Based on the loading 
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capacity of the DMARD nanoparticles (0.1 mg/mg), the free DMARDs were administrated at 
equal weight concentration relative to the DMARDs within the nanoparticles. Thus, the results 
thus suggested that the DMARD-loaded nanoparticles possessed therapeutic efficacies that were 
nearly equivalent to those of the free DMARDs. When applied in vivo, this is expected to 
translate to greater success based on passive targeting of the nanoparticles to the inflamed tissue.   
6.5 Conclusion 
 PSA-TMC nanoparticles were previously developed for targeted delivery in the treatment 
of RA to enhance therapeutic efficacy and reduce non-specific cytotoxicity of DMARDs. The 
physical characteristics and DMARD-loading capacity of the nanoparticles were suggestive of a 
suitable carrier system. In this study, an RA in vitro model was used to validate that two 
common DMARDs, MTX and DM, elicited a desirable, anti-inflammatory therapeutic response 
when entrapped in nanoparticles. The present study provided the foundation for future in vivo 
studies aimed towards demonstrating the site-specific nature of the nanoparticles and the 
enhanced efficacy of nanoparticle entrapped DMARDs.  
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Chapter 7 Summary  
In sum, two PSA-based micelle systems and one PSA-based nanoparticle system were 
successfully developed based on the needs of RA. These PSA-based nanocarriers were 
characterized in terms of composition, size, surface charge, morphology, drug loading and 
release, toxicity, cellular uptake, and anti-inflammatory efficacy. Results showed that the PSA-
based nanocarriers possessed proper sizes between 70-120 nm for passive targeting to inflamed 
tissues and had high stability, as indicated by high zeta potential values (absolute value larger 
than 30 mV) and low polydispersity index (PDI). These nanocarriers had been demonstrated to 
carry sufficient amount of model drugs, specifically methotrexate, dexamethasone, and 
cyclosporine A, via physical interactions and to release the drugs in a controllable manners. 
PSA-PCL micelles and PSA-TMC nanoparticles were non-cytotoxic, as indicated by high IC50 
values, while PSA-DA was cytotoxic. Fluorescent microscopy demonstrated that synovial cells 
effectively internalized PSA-PCL micelles and PSA-TMC nanoparticles within a short 
incubation time (60 min). More significantly, DM-loaded and MTX-loaded PSA-TMC 
nanoparticles had significantly suppressed the secretion of pro-inflammatory proteins by 
inflamed synovial cells.  
To conclude, PSA-PCL micelles and PSA-TMC nanoparticles were good carriers for 
drugs because of their low toxicity, proper size, good drug loading properties, capacity to deliver 
drugs, and anti-inflammatory efficacy. Therefore, these two systems could serve as anti-
inflammatory drug delivery systems. Addition of an active targeting group and/or stimuli-
sensitive moieties to PSA-PCL micelles and PSA-TMC nanoparticles might endow them with 
enhanced anti-inflammatory efficacy and increased specificity to diseased tissues. 
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Chapter 8 Future work  
 PSA-PCL micelles and PSA-TMC nanoparticles were successfully developed in this 
dissertation. As discussed in separate chapters, PSA-PCL micelles and PSA-TMC nanoparticles 
possessed small size 70-120 nm, which presumably would target inflamed tissues with enhanced 
permeability of vasculature in vivo. In future, animal models with inflammatory arthritis will be 
established to test the hypothesis.   
 Hyaluronic acid (HA) is a natural component in the extracellular matrix (ECM) of human 
joints that has high affinity to CD 44 receptors. Based on the overexpression of the CD 44 
receptors by inflamed synovial fibroblasts, we hypothesize that addition of HA to our established 
PSA-based nanocarriers will enhance the anti-inflammatory efficacy of associated therapeutics. 
In preliminary studies, we have fabricated stable HA-g-PSA-TMC nanoparticles.  
First, HA oligomer was obtained via enzymatic degradation. 100 mg HA was added to 25 
ml PBS solution under stirring at pH 6.5. 2.4 mg hyaluronidase was added to solution and 
solution was stirring for 1 h at 37 °C and then 20 min at 95 °C. This protocol was established 
based on unpublished data from Gel Permeability Chromatograph (GPC). 
 Second, PSA was reacted with crosslinker adipic dihydrazide (ADH) (Figure 27). 
Briefly, 150 mg PSA (0.485 mmol sialic acid), 15 mg EDC (0.097 mmol), and 11 mg NHS 
(0.097 mmol) were added into 15 ml DI water and pH of solution was adjusted to 4.5. After 30 
min, 8.5 mg ADH (0.0485 mmol) was added to solution and reaction was continued for 2 h. pH 
was adjusted to 7.0 to quench the reaction and after filtration, reaction solution was dialysis 
against DI water overnight. Finally, purified solution was lyophilized to produce PSA-ADH. 1H 
NMR was conducted to confirm the structure of product.  
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At last, HA was grafted onto PSA via cross-linker ADH (Figure 27). 72.8 mg HA 
(0.02425 mmol HA oligomer), 7.5 mg EDC (0.0485 mmol), and 5.6 mg NHS (0.0485 mmol) 
were dissolved in 20 ml DI water and pH of the solution was adjusted to 4.5. 150 mg PSA-ADH 
(0.0485 mmol sialic acid) was added to the solution after 30 min. The reaction was continued for 
2 h and was quenched via adjusting pH to 7.0. Reaction solution was then dialyzed for 2 days 
and lyophilized to obtain the final product: HA-g-PSA. 1H-NMR was conducted to confirm the 
structure of product (Figure 40).  
 
Figure 27. Synthesis of HA-grafted-PSA 
 Two ratios of TMC: HA-g-PSA and two centrifuge speeds were used to explore an 
optimal formulation for HA-g-PSA-TMC nanoparticles. Nanoparticles were prepared according 
to previously published method [1]. Briefly, 6.4 mg TMC was dissolved into 3 ml 0.3% acetic 
acid solution and 3.2 mg (TMC: HA-g-PSA 1:0.5) or 6.4 mg (TMC: HA-g-PSA 1:1) HA-g-PSA 
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was mixed into 2 ml DI water with 1 mg TPP. HA-g-PSA solution was added dropwise into 
TMC solution and the mixed solution was stirred for 20 min. Centrifuge at 2000 rpm or 3000 
rpm was performed for 5 min to harvest a white nanoparticle pellet at the bottom. Excess 
supernatant was removed.  
 The size and zeta potential of HA-g-PSA-TMC nanoparticles were measured using a 
Malvern Zetasize NanoZS90 (Malvern Instruments Ltd., Malvern, UK). The particle size 
distribution of the nanoparticles was reported as a PDI. The nanoparticles were dissolved in DI 
water at 2 mg/ml and used without filtration. Then, the nanoparticle solutions were transferred to 
disposable microcuvettes (Malvern Instruments Ltd., Malvern, UK) for size measurements and 
disposable capillary cells (Malvern Instruments Ltd., Malvern, UK) for zeta potential 
measurements. For dynamic light scattering measurements, the temperature was set 25 °C, and 
the scattered light was detected at an angle of 173 °. All measurements were performed in 
triplicate. Results showed that among different formulations and centrifuge speeds, the most 
stable nanoparticle was TMC: HA-g-PSA 1:1 centrifuged at 3000 rpm 5 min and the HA-g-PSA-
TMC nanoparticles maintained a small size (Figure 28). 
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Figure 28. Size (top), zeta potential (middle), and polydispersity (PDI) (bottom) of two 
formulations, TMC: HA-g-PSA 1: 0.5 and 1:1 after centrifuge at 2000 rpm or 3000 rpm 5 min. * 
indicated a significant difference versus the formulation, TMC: HA-g-PSA 1: 0.5  (N=3, P<0.05) 
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Uptake of HA-g-PSA-TMC nanoparticles by SW982 cells was verified and compared to 
PSA-TMC nanoparticles via inverted fluorescence microscopy. The SW982 cells were added to 
lysine coated Lab-Tek ® Chamber Slides, and fluorescently tagged HA-g-PSA-TMC 
nanoparticles or PSA-TMC nanoparticles (Sulforhodamine 101 cadaverine) were added 24 h 
after seeding. After a short incubation period (45 min), nanoparticle solution was removed and 
cells were washed with PBS for three times. Fluorescence signal was observed with a Nikon 
Eclipse Ti inverted microscope. The incubation period was selected based on prior optimization 
experiments and is consistent with other researchers with regards to the short time necessary to 
observe uptake of chitosan-based nanoparticles. 
 HA-g-PSA-TMC nanoparticles showed higher cellular internalization by SW982 cells 
relative to PSA-TMC nanoparticles presumably via interaction with overexpressed CD 44 
receptors (Figure 29). In future, more comprehensive experiments will be conducted to explore 
the mechanism of cellular uptake of HA-g-PSA-TMC nanoparticles by SW982 cell. In addition, 
drug-loaded HA-g-PSA-TMC nanoparticles will be used to treat inflamed synovial cells and 
their anti-inflammatory efficacy will be compared to PSA-TMC nanoparticles by analyzing the 
suppression of pro-inflammatory proteins. 
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Figure 29. Color composite of fluorescence microscopy images demonstrating nanoparticle 
uptake at room temperature by human synovial sarcoma SW982 cells. To facilitate fluorescence 
microscopic evaluation, PSA was conjugated to sulforhodamine 101 cadaverine. Use of identical 
imaging settings permits direct comparison of fluorescence intensities. Higher intensities 
indicated more cellular uptake of nanoparticle by cells. Left image: cells not incubated with 
nanoparticles results in negligible signal. Middle image: cells incubated with nanoparticles and 
showed active cellular uptake. Right image: cells incubated with HA-coated nanoparticles and 
demonstrated enhanced cellular uptake. All three groups were incubated for 60 min and washed 
three times with PBS before imaging. 
 PSA-PCL micelles have been shown to possess a small size and effectively deliver the 
immunosuppressive drug-Cyclosporine A (CyA). In preliminary experiments, HA has been 
grafted onto PSA-PCL micelles for the encapsulation of hydrophobic drugs to achieve enhanced 
cellular uptake and improved specificity in vitro and in vivo (Figure 30). Degree of substitution 
of HA oligomer was low to maintain small size of micelles and prevented potential clearance of 
HA-g-PSA-PCL micelles by the interaction of HA to HA receptor for endocytosis (HARE) in the 
liver. HA-g-PSA-PCL micelles have shown a high capacity of simvastatin and lovastatin (Table 
9). Fluorescence experiment has been performed to explore and compare cellular uptake of PSA-
PCL micelles within/out HA.  	  
Control 
10 µm 
PSA-TMC 
10 µm 
TMC-PSA-HA 
10 µm 
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Figure 30. Synthesis of HA-g-PSA-PCL.  
Table 9. Loading capacity and loading efficiency of hydrophobic statins with HA-g-PSA-PCL 
micelles.  
 LE (%) LC(mg drug/mg micelle) 
Lovastatin  58 0.17 
Simvastatin  57 0.14 	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Figure 31. Color composite of fluorescence microscopy images demonstrating micelle uptake at 
room temperature by primary vascular smooth muscle cells. To facilitate fluorescence 
microscopic evaluation, PSA was conjugated to sulforhodamine 101 cadaverine. Use of identical 
imaging settings permits direct comparison of fluorescence intensities. Higher intensities 
indicated more cellular uptake of nanoparticle by cells. Left image: cells incubated with PSA-
PCL micelles results in weak signal. Right image: cells incubated with HA-g-PSA-PCL micelles 
and demonstrated enhanced cellular uptake. Both groups were incubated for 60 min and washed 
three times with PBS before imaging. 
In future, statin-loaded HA-g-PSA-PCL micelles will be used to evaluate the anti-
proliferation and anti-inflammatory efficacy by inflamed vascular smooth muscle cells that are 
highly involved in cardiovascular diseases. 
 The next stage of research will be a series of in vivo investigation. Inflamed arthritis mice 
will be injected with nanocarriers, drug-loaded nanocarriers, drug-loaded HA-nanocarriers to 
study the interaction of these nanocarriers with organs, tissues, and cells in terms of their 
distribution, circulation, interaction with blood, efficacy of treatment. Outcomes will be 
compared to free drug treatment and biopsy of joint tissues will be performed at 7 days, 14 days, 
and 28 days after administration to explore preservations of joints. 
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 Other future directions can be the application of (HA-g)-PSA-PCL micelles and (HA-g)-
PSA-TMC nanoparticles for drug delivery to other drugs like genes and proteins and other 
diseases, such as infection, cardiovascular diseases, and cancer.  
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APPENDIX A: SPECTRA 
	  
Figure 32. 1H NMR spectrum (D2O, water suppression) of polysialic acid. 
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Figure 33. 1H NMR spectrum (D2O, water suppression) of decylamine modified polysialic acid 
with a DS of approximately 60%.   
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Figure 34. Mass spectra of amine-terminated CyA 
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Figure 35. 1H NMR spectrum (CDCl3) of polycaprolactone (PCL). 
  
134 
	  
Figure 36. 1H NMR spectrum (CDCl3) of PCL-boc-glycine. 
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Figure 37. 1H NMR spectrum (CDCl3) of PCL-amine. 
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Figure 38. 1H NMR spectrum (D2O, water suppression) of PSA- PCL. 
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Figure 39. 1H NMR spectrum (D2O, water suppression) of N, N, N-trimethyl chitosan (TMC) 
with a DS of approximately 50%.   
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Figure 40. 1H NMR spectrum (D2O, water suppression) of HA-g-PSA. 
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APPENDIX B: SUPPLEMENTAL IMAGES OF PSA-
PCL MICELLES 
Quantitative fluorescence microscopy 
Images of cells were taken at identical illumination and exposure settings. The resulting images 
spanned a very large dynamic range that made it not possible to show images at the same 
brightness settings. Figure 41 showed the images at settings where the 60 min incubation at room 
temperature was well visible. At these settings the features in the images at 4°C were barely 
visible. Conversely, at settings that allowed seeing the features in the images at 4°C, the room 
temperature images were highly oversaturated (Figure 42). Thus, the images presented in chapter 
4 (Figure 15, 16) had different brightness settings for the room temperature and 4°C images, but 
it was clear from the images here that the amount of drug-loaded micelle uptake was 
dramatically different at room temperature when compared to incubation at 4°C. 
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Figure 41. Color composite of fluorescence microscopy images demonstrating nanoparticle 
uptake and drug release at room temperature. Use of identical imaging settings did not allow for 
identification of the features in all the images. Here, brightness and contrast were adjusted such 
that the brightest image (room temperature, 60 min incubation (top right image)) was well 
visible. The features in the 4°C images (middle and right images in the bottom row) were almost 
invisible at these parameters. Scale bars were 5 µm. 
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Figure 42. Color composite of fluorescence microscopy images demonstrating nanoparticle 
uptake and drug release at room temperature. Use of identical imaging settings did not allow for 
identification of the features in all the images. Here, brightness and contrast were adjusted such 
that the features in the lower signal images at 4°C were visible (middle and right images in the 
bottom row). At these settings the room temperature images were so oversaturated that the 
features completely disappeared (room temperature, 60 min incubation (top right image)). Scale 
bars were 5 µm. 
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